ibuprofen has been researched along with Ductus Arteriosus, Patent in 411 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
Ductus Arteriosus, Patent: A congenital heart defect characterized by the persistent opening of fetal DUCTUS ARTERIOSUS that connects the PULMONARY ARTERY to the descending aorta (AORTA, DESCENDING) allowing unoxygenated blood to bypass the lung and flow to the PLACENTA. Normally, the ductus is closed shortly after birth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the effects of early echocardiography-targeted ibuprofen treatment of large patent ductus arteriosus (PDA) on survival without cerebral palsy at 24 months of corrected age." | 9.41 | Effect of Early Targeted Treatment of Ductus Arteriosus with Ibuprofen on Survival Without Cerebral Palsy at 2 Years in Infants with Extreme Prematurity: A Randomized Clinical Trial. ( Beuchee, A; Cambonie, G; Clyman, R; Debillon, T; Durrmeyer, X; Favrais, G; Flamant, C; Gascoin, G; Le Thuaut, A; Ligi, I; Patkai, J; Rozé, JC, 2021) |
| "Hemodynamically significant patent ductus arteriosus (hsPDA) in very low birth weight (VLBW) infants is routinely treated in many countries with oral ibuprofen." | 8.02 | Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus. ( Guo, H; Huang, Y; Lin, HC; Liu, H; Peng, H; Shen, X; Yao, S; Zhou, M; Zhou, P, 2021) |
| "To evaluate the association of ibuprofen exposure with the risk of bronchopulmonary dysplasia (BPD) in extremely premature infants." | 7.96 | Neonatal ibuprofen exposure and bronchopulmonary dysplasia in extremely premature infants. ( Chen, X; Huang, Z; Lin, Y; Qiu, X; Sun, P; Walther, FJ; Yang, C, 2020) |
| "There is a linear relationship between infant birth weight and PDA treatment: the failure rate of a first course of ibuprofen increases with increasing degree of growth restriction." | 7.81 | Efficacy of a first course of Ibuprofen for patent ductus arteriosus closure in extremely preterm newborns according to their gestational age-specific Z-score for birth weight. ( Aubelle, MS; Gascoin, G; Jarreau, PH; Lopez, E; Madeleneau, D; Patkai, J; Pierron, C; Roze, JC, 2015) |
| "To document trends and covariates of creatinemia (Scr) in extremely low birth weight (ELBW, < 1,000 g) neonates, maternal characteristics [betamethasone, premature preterm rupture of membranes (PPROM), pre-eclampsia, maternal Scr], characteristics at delivery [gestational age (GA), birth weight (BW), small for GA (SGA), Apgar, intubation] and during neonatal stay [ventilation, oxygen, parenteral nutrition, ibuprofen, steroids, intraventricular hemorrhage, retinopathy of prematurity (ROP), phototherapy] were linked with Scr observations." | 7.77 | Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) neonates. ( Allegaert, K; George, I; Levtchenko, E; Mekahli, D; Rayyan, M, 2011) |
| " Recently, we gave L-lysine ibuprofen to a preterm infant with respiratory distress to induce closure of a patent ductus arteriosus, and the infant experienced pulmonary hypertension." | 7.73 | Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus. ( Bellini, C; Campone, F; Serra, G, 2006) |
| "To discuss intestinal side effects of ibuprofen in the treatment of patent ductus arteriosus, after having observed two cases of spontaneous intestinal perforation following ibuprofen treatment." | 7.72 | Spontaneous intestinal perforation after oral ibuprofen treatment of patent ductus arteriosus in two very-low-birthweight infants. ( Demir, K; Duman, N; Gurcu, O; Kumral, A; Ozkan, H; Tatli, MM, 2004) |
| "This study evaluates the effects of Indomethacin (IND), Prostaglandin E1 (PGE1), and Ibuprofen (IBP) in a bowel ischemia model." | 7.66 | Comparative effects of indomethacin, prostaglandin E1, and ibuprofen on bowel ischemia. ( Cikrit, D; Grosfeld, JL; Gross, K; Kamman, K; Katz, S; Ross, D; Weber, TR; Wolfe, M, 1983) |
| "Expectant management for PDA in extremely premature infants was noninferior to early ibuprofen treatment with respect to necrotizing enterocolitis, bronchopulmonary dysplasia, or death at 36 weeks' postmenstrual age." | 5.69 | Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus. ( Avino, D; de Baat, T; De Bisschop, B; de Boode, WP; de Vries, WB; Derriks, F; Dijk, PH; Dijkman, KP; Donders, R; Henriksen, TB; Hocq, C; Hundscheid, T; Kooi, EMW; Kroon, AA; Kyng, KJ; Meeus, M; Mulder, AL; Mulder-de Tollenaer, SM; Nuytemans, DHGM; Onland, W; van Kaam, AH; Van Overmeire, B; Vijlbrief, DC; Villamor, E; Visser, R; Zecic, A, 2023) |
| "To examine the effects of early echocardiography-targeted ibuprofen treatment of large patent ductus arteriosus (PDA) on survival without cerebral palsy at 24 months of corrected age." | 5.41 | Effect of Early Targeted Treatment of Ductus Arteriosus with Ibuprofen on Survival Without Cerebral Palsy at 2 Years in Infants with Extreme Prematurity: A Randomized Clinical Trial. ( Beuchee, A; Cambonie, G; Clyman, R; Debillon, T; Durrmeyer, X; Favrais, G; Flamant, C; Gascoin, G; Le Thuaut, A; Ligi, I; Patkai, J; Rozé, JC, 2021) |
| "Presence of symptomatic patent ductus arteriosus is common in small preterm infants and ibuprofen is commonly used for its medical closure." | 5.39 | Pulmonary hypertension in an infant treated with ibuprofen. ( Kumarshingri, PS; Sehgal, A, 2013) |
| "Course of sepsis was evaluated by CRP and IL-6 levels." | 5.38 | The effects of ibuprofen on sepsis parameters in preterm neonates. ( Canpolat, FE; Celik, IH; Demirel, G; Dilmen, U; Erdeve, O; Oguz, SS, 2012) |
| "Pulmonary hypertension is a rare but potentially fatal complication of ibuprofen administration in preterm infants." | 5.38 | Severe pulmonary hypertension with therapeutic L-lysine ibuprofen in 2 preterm neonates. ( Aghai, ZH; Amendolia, B; Bhat, V; Lynn, M; Ritz, SB, 2012) |
| "This study aims to determine whether or not treatment of preterm neonates with PDA using IV ibuprofen can impair renal function and in what range of birth weights and gestational ages the risk of major renal side-effects due to ibuprofen is highest." | 5.17 | Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. ( Bagnoli, F; Casucci, M; Messina, G; Mori, A; Rossetti, A; Tomasini, B, 2013) |
| "A follow-up study of 99 infants with birth weight ≤ 1,500 g and gestational age ≤ 32 weeks who received either oral or intravenous ibuprofen for patent ductus arteriosus was conducted to assess at 18 to 24 months (corrected age), abnormal neurological, neurosensory, and cognitive impairment were defined as follows:neurological outcomes included moderate/severe cerebral palsy, neurosensory outcomes included bilateral hearing loss and blindness in either eye, and cognitive impairment included mental developmental index score < 70." | 5.17 | Impact of oral versus intravenous ibuprofen on neurodevelopmental outcome: a randomized controlled parallel study. ( Dilmen, U; Eras, Z; Erdeve, O; Gokmen, T; Ozyurt, BM; Saridas, B, 2013) |
| "Ibuprofen therapy on the third day of life is as efficacious as indomethacin for the treatment of patent ductus arteriosus in preterm infants with the respiratory distress syndrome and is significantly less likely to induce oliguria." | 5.09 | A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. ( Degroote, K; Langhendries, JP; Lecoutere, D; Smets, K; Van de Broek, H; Van Overmeire, B; Weyler, J, 2000) |
| " Moderate certainty evidence showed a reduction in NEC following administration of a combination of species of probiotics, probiotics (any), antenatal corticosteroids in pregnant women at risk of preterm birth, and ibuprofen versus indomethacin for treatment of patent ductus arteriosus (PDA)." | 5.05 | An Overview of Systematic Reviews of Randomized-Controlled Trials for Preventing Necrotizing Enterocolitis in Preterm Infants. ( Ei-Saie, A; Maheshwari, A; Neu, J; Pammi, M; Xiong, T, 2020) |
| "A high dose of oral ibuprofen was associated with a higher likelihood of hemodynamically significant PDA closure vs standard doses of intravenous ibuprofen or intravenous indomethacin; placebo or no treatment did not significantly change the likelihood of mortality, necrotizing enterocolitis, or intraventricular hemorrhage." | 4.98 | Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis. ( Florez, ID; Mbuagbaw, L; Mitra, S; Sadeghirad, B; Tamayo, ME; Thabane, L; Vanniyasingam, T; Veroniki, AA; Zea, AM; Zhang, Y, 2018) |
| " Oral ibuprofen is associated with lower instance of necrotizing enterocolitis." | 4.95 | Patent Ductus Arteriosus in the Preterm Infant: Diagnostic and Treatment Options. ( Keim-Malpass, J; Prescott, S, 2017) |
| " Up to the present day, several cases of severe and sometimes irreversible renal insufficiency have been described in neonates exposed to indomethacin prenatally or in the first days of life for treatment of patent ductus arteriosus (PDA)." | 4.81 | NSAID-induced nephrotoxicity from the fetus to the child. ( Cuzzolin, L; Dal Cerè, M; Fanos, V, 2001) |
| "Hemodynamically significant patent ductus arteriosus (hsPDA) in very low birth weight (VLBW) infants is routinely treated in many countries with oral ibuprofen." | 4.02 | Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus. ( Guo, H; Huang, Y; Lin, HC; Liu, H; Peng, H; Shen, X; Yao, S; Zhou, M; Zhou, P, 2021) |
| "To evaluate the association of ibuprofen exposure with the risk of bronchopulmonary dysplasia (BPD) in extremely premature infants." | 3.96 | Neonatal ibuprofen exposure and bronchopulmonary dysplasia in extremely premature infants. ( Chen, X; Huang, Z; Lin, Y; Qiu, X; Sun, P; Walther, FJ; Yang, C, 2020) |
| "Gastrointestinal complications observed in infants treated with ibuprofen for PDA including gastrointestinal perforations occur in less mature infants." | 3.96 | Adverse events related to ibuprofen treatment for patent ductus arteriosus in premature neonates. ( Berthiller, J; Bouamari, H; Claris, O; Ndour, D; Nguyen, KA; Plaisant, F, 2020) |
| "Male gender, chorioamnionitis, early sepsis, asphyxia, hemodynamic PDA, persistent hypotension, ibuprofen and paracetamol usage, and orogastric catheter administration were the main risk factors for gastric perforations in VLBW infants." | 3.88 | Neonatal gastric perforations in very low birth weight infants: a single center experience and review of the literature. ( Babayigit, A; Cetinkaya, M; Ozaydın, S; Sander, S, 2018) |
| " Twelve risk factors for dTSH were identified on univariate analysis: cesarean section, mechanical ventilation, patent ductus arteriosus (PDA), pneumothorax, and administration of cefotaxime, vancomycin, fluconazole, dopamine, ibuprofen, furosemide, insulin, and packed red blood cells." | 3.85 | Risk Factors for the Development of Delayed TSH Elevation in Neonatal Intensive Care Unit Newborns. ( Almashanu, S; Bier Palmon, R; Eventov-Friedman, S; Flidel-Rimon, O; Golan, A; Kats, N; Keidar, R; Marom, R; Troitzky, M; Zung, A, 2017) |
| "There is a linear relationship between infant birth weight and PDA treatment: the failure rate of a first course of ibuprofen increases with increasing degree of growth restriction." | 3.81 | Efficacy of a first course of Ibuprofen for patent ductus arteriosus closure in extremely preterm newborns according to their gestational age-specific Z-score for birth weight. ( Aubelle, MS; Gascoin, G; Jarreau, PH; Lopez, E; Madeleneau, D; Patkai, J; Pierron, C; Roze, JC, 2015) |
| "To compare the incidence of medical closure of patent ductus arteriosus (PDA) and adverse events (acute renal dysfunction, necrotizing enterocolitis, spontaneous intestinal perforation, and gastrointestinal bleeding) between preterm infants who received indomethacin and ibuprofen for the treatment of PDA." | 3.79 | Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants. ( Bali, V; Harabor, A; Kamaluddeen, M; Sivanandan, S; Soraisham, AS, 2013) |
| "In infants with VLBW, oral ibuprofen is as effective as intravenous indomethacin for closure of PDA and is associated with significantly fewer cases of necrotizing enterocolitis among infants with birth body weights <1250 g and significantly lower rates of elevated creatinine levels among neonates with birth body weights ranging from 1000 to 1500 g." | 3.78 | Oral ibuprofen versus intravenous indomethacin for closure of patent ductus arteriosus in very low birth weight infants. ( Chen, HN; Hsiao, CC; Lee, CH; Lee, ML; Tsao, LY, 2012) |
| "A prospective study with subjects serving as their own controls was performed on <30 weeks' gestational age infants with unconjugated hyperbilirubinemia and who received ibuprofen for patent ductus arteriosus." | 3.77 | Effect of ibuprofen on bilirubin-albumin binding affinity in premature infants. ( Amin, SB; Miravalle, N, 2011) |
| "To document trends and covariates of creatinemia (Scr) in extremely low birth weight (ELBW, < 1,000 g) neonates, maternal characteristics [betamethasone, premature preterm rupture of membranes (PPROM), pre-eclampsia, maternal Scr], characteristics at delivery [gestational age (GA), birth weight (BW), small for GA (SGA), Apgar, intubation] and during neonatal stay [ventilation, oxygen, parenteral nutrition, ibuprofen, steroids, intraventricular hemorrhage, retinopathy of prematurity (ROP), phototherapy] were linked with Scr observations." | 3.77 | Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) neonates. ( Allegaert, K; George, I; Levtchenko, E; Mekahli, D; Rayyan, M, 2011) |
| " The levels of NT-proBNP in premature neonates with hemodynamically significant patency of the ductus arteriosus (hsPDA) were assessed before and after treatment using ibuprofen, indomethacin, or both." | 3.76 | N-terminal-pro-B-type natriuretic peptide in premature patent ductus arteriosus: a physiologic biomarker, but is it a clinical tool? ( Bromiker, R; Hammerman, C; Kaplan, M; Nir, A; Schimmel, MS; Shchors, I, 2010) |
| "Treatment of a patent ductus arteriosus with COX-inhibitors such as indomethacin and ibuprofen, increases the risk for bronchopulmonary dysplasia without reducing other complications or death." | 3.75 | [Patent ductus arteriosus in premature infants]. ( Bratlid, D; Farstad, T, 2009) |
| " Recently, we gave L-lysine ibuprofen to a preterm infant with respiratory distress to induce closure of a patent ductus arteriosus, and the infant experienced pulmonary hypertension." | 3.73 | Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus. ( Bellini, C; Campone, F; Serra, G, 2006) |
| "To discuss intestinal side effects of ibuprofen in the treatment of patent ductus arteriosus, after having observed two cases of spontaneous intestinal perforation following ibuprofen treatment." | 3.72 | Spontaneous intestinal perforation after oral ibuprofen treatment of patent ductus arteriosus in two very-low-birthweight infants. ( Demir, K; Duman, N; Gurcu, O; Kumral, A; Ozkan, H; Tatli, MM, 2004) |
| "This study evaluates the effects of Indomethacin (IND), Prostaglandin E1 (PGE1), and Ibuprofen (IBP) in a bowel ischemia model." | 3.66 | Comparative effects of indomethacin, prostaglandin E1, and ibuprofen on bowel ischemia. ( Cikrit, D; Grosfeld, JL; Gross, K; Kamman, K; Katz, S; Ross, D; Weber, TR; Wolfe, M, 1983) |
| "In very preterm infants on significant respiratory support, low dose-short course intravenous paracetamol treatment was non-inferior to a conventional dosing regime of paracetamol for closure of hsPDA in the first week of postnatal age." | 3.30 | Low dose paracetamol for management of patent ductus arteriosus in very preterm infants: a randomised non-inferiority trial. ( Balasubramanian, H; Bhalgat, P; Jain, V; Kabra, N; Mohan, D; Parikh, S; Sheth, K, 2023) |
| "For premature infants with respiratory failure combined with PDA, cardiopulmonary ultrasonography can better guide respiratory support." | 3.30 | Cardiopulmonary Ultrasound-Guided Treatment of Premature Infants with Respiratory Failure and Patent Ductus Arteriosus: A Randomized, Controlled Trial. ( Hua, L; Jia, X; Lou, X; Xu, L; Zhang, Z; Zhao, M, 2023) |
| " Although the use of indomethacin is the standard therapy for PDA, it is sometimes not applicable because of its adverse effects, such as renal and platelet dysfunctions." | 3.30 | iPAPP: study protocol for a multicentre randomised controlled trial comparing safety and efficacy of intravenous paracetamol and indomethacin for the treatment of patent ductus arteriosus in preterm infants. ( Fukuoka, N; Honda, M; Kawada, K; Kikuchi, K; Mikami, M; Motojima, Y; Namba, F; Ogawa, K; Sakatani, S; Sako, M; Ueda, K, 2023) |
| "Acetaminophen was first proposed as a potential treatment for PDA in 2011." | 3.01 | Acetaminophen for the patent ductus arteriosus: has safety been adequately demonstrated? ( Jensen, EA; McCulley, DJ; Mitra, S; Wright, CJ, 2023) |
| "IV indomethacin was more effective than IV acetaminophen for treatment of hsPDAs." | 3.01 | A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants. ( Davidson, JM; Ferguson, J; Ivey, E; Philip, R; Talati, AJ; Weems, MF, 2021) |
| "The question of whether to treat patent ductus arteriosus (PDA) early or wait until symptoms appear remains high on the research agenda for neonatal medicine." | 3.01 | Study protocol: baby-OSCAR trial: Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial. ( Bell, JL; Edwards, C; Field, D; Gupta, S; Hardy, P; Hutchison, E; Johnson, S; Juszczak, E; Kelsall, W; Laube, M; Linsell, L; Pepperell, J; Roberts, T; Sinha, S; Stanbury, K; Subhedar, N; Wyllie, J, 2021) |
| " The secondary outcomes include components of the primary outcome as well as clinical outcomes related to response to treatment or adverse effects of treatment." | 3.01 | Relative effectiveness and safety of pharmacotherapeutic agents for patent ductus arteriosus (PDA) in preterm infants: a protocol for a multicentre comparative effectiveness study (CANRxPDA). ( Abou Mehrem, A; Adie, M; Alvaro, R; Ben Fadel, N; Bhattacharya, S; Bodani, J; Canning, R; Dorling, J; Drolet, C; Gardner, CE; Hatfield, T; Hyderi, A; Jain, A; Jasani, B; Kanungo, J; Khurshid, F; Kumaran, K; Lapointe, A; Louis, D; Mitra, S; Morin, A; Shah, P; Soraisham, A; Stavel, M; Ting, JY; Weisz, D; Ye, XY, 2021) |
| "Indomethacin was more effective than acetaminophen in producing ductus constriction." | 2.90 | Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320). ( Aucott, SW; Bulbul, A; Carey, WA; Clyman, RI; Derrick, M; Dong, L; Erdeve, O; Farooqi, A; Håkansson, S; Hassinger, DC; Hayashi, M; Heuchan, AM; Kaempf, J; Katheria, A; Kimball, A; Leone, T; Liebowitz, M; Lindqvist, J; Nelson, K; Perez, J; Sankar, M; Sauberan, J; Serize, A; Singh, J; Wickremasinghe, A; Wolf, IS, 2019) |
| "Optimal management of the patent ductus arteriosus (PDA) in preterm infants remains controversial." | 2.84 | Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants. ( Bell, EF; Bethany Ball, M; Boghossian, NS; Brumbaugh, JE; Dagle, JM; Das, A; Do, BT; Sanchez, PJ; Shankaran, S; Stoll, BJ; Vohr, BR; Wyckoff, MH, 2017) |
| "The indomethacin group was associated with a significantly higher chance of persistent ductal response than the ibuprofen group (66 vs." | 2.84 | Randomized Trial to Compare Renal Function and Ductal Response between Indomethacin and Ibuprofen Treatment in Extremely Low Birth Weight Infants. ( Chen, CM; Florens, A; Huang, FK; Kuo, YT; Lin, YJ; Rehan, VK; Tsai, ML; Wu, SY; Yeh, TF, 2017) |
| " However, paracetamol caused fewer adverse effects." | 2.82 | Comparative safety and efficacy of paracetamol versus non-steroidal anti-inflammatory agents in neonates with patent ductus arteriosus: A systematic review and meta-analysis of randomized controlled trials. ( Chatziravdeli, VI; Dardiotis, E; Doxani, C; Katsaras, DN; Katsaras, GN; Mitsiakos, G; Papavasileiou, GN; Stefanidis, I; Touloupaki, M, 2022) |
| "The hemodynamic impact of persistent patent ductus arteriosus (PDA) is associated with neonatal morbidities and mortality in preterm newborns." | 2.82 | Efficacy and Costs of Three Pharmacotherapies for Patent Ductus Arteriosus Closure in Premature Infants. ( Vidavalur, R, 2022) |
| "To evaluate the efficacy of dual patent ductus arteriosus (PDA) pharmacotherapy compared to monotherapy we searched Medline, Embase, Cochrane Library, and references of relevant articles through October 20, 2021 for randomized clinical trials (RCTs) and cohort studies comparing dual PDA treatment vs." | 2.82 | Dual Therapy vs. Monotherapy for the Patent Ductus Arteriosus: A Systematic Review. ( Abdaljalil, H; Abu-Omar, R; Bin-Nun, A; Hammerman, C; Kasirer, Y; Mimouni, F; Nitzan, I; Schorrs, I, 2022) |
| "Based on low-grade evidence, high dose ibuprofen may more effectively reduce rates of PDA ligation compared to standard dose with no increase in adverse effects, neonatal morbidities and mortality." | 2.82 | Efficacy and safety of high versus standard dose ibuprofen for patent ductus arteriosus treatment in preterm infants: A systematic review and meta-analysis. ( Jain, A; Jasani, B; Shahroor, M; Weisz, D; Yeung, T, 2022) |
| "The different management strategies for patent ductus arteriosus (PDA) in preterm infants are expectant management, surgery, or medical treatment with non-selective cyclo-oxygenase inhibitors." | 2.82 | Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. ( Jasani, B; Mitra, S; Shah, PS, 2022) |
| " Although ibuprofen represents the first choice for the closure of PDA, this treatment can cause severe gastrointestinal and adverse renal effects and worsen platelet function." | 2.82 | Efficacy and safety of intravenous paracetamol in comparison to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: study protocol for a randomized control trial. ( Comandini, A; Dani, C; Lipone, P; Lista, G; Mosca, F; Poggi, C; Ramenghi, L; Romagnoli, C; Rosignoli, MT; Salvatori, E; Schena, F, 2016) |
| "Echocardiographically guided ibuprofen treatment of patent ductus arteriosus is feasible and reduces unnecessary doses of medication." | 2.79 | Randomised controlled clinical trial of standard versus echocardiographically guided ibuprofen treatment for patent ductus arteriosus in preterm infants: a pilot study. ( Bravo, MC; Cabañas, F; Pellicer, A; Pérez-Fernández, E; Pérez-Rodríguez, J; Quero, J; Riera, J, 2014) |
| "Ibuprofen (IBU) has proved as effective as indomethacin in the pharmacological closure of hemodynamically significant patent ductus arteriosus (HsPDA), with an efficacy inversely related to gestational age (57-89%)." | 2.79 | Continuous infusion of ibuprofen for treatment of patent ductus arteriosus in very low birth weight infants. ( Chiandetti, L; Frigo, AC; Lago, P; Opocher, F; Ricato, S; Salvadori, S, 2014) |
| " Patients were assigned to receive either oral ibuprofen at a dosage of 10, 5, 5 mg/kg every 24 h or three doses of oral indomethacin (0." | 2.79 | Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. ( Agarwal, S; Anand, P; Dubey, NK; Dudeja, A; Maria, A; Yadav, DK; Yadav, S, 2014) |
| " Target concentration approach by the evaluation of trough level may be applicable to real-time dosing strategy." | 2.78 | The relationship between trough drug concentrations and ductal closure in preterm infants treated with three-dose-oral ibuprofen. ( Dilmen, U; Erdeve, O; Oncel, MY; Ozdemir, R; Yurttutan, S, 2013) |
| "Oral ibuprofen has demonstrated good effects on symptomatic patent ductus arteriosus (PDA) but with many contraindications and potential side-effects." | 2.78 | Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. ( Dang, D; Wang, D; Wu, H; Zhang, C; Zhou, Q; Zhou, W, 2013) |
| "Ibuprofen treatment within the first 5 days of life was indicated when at least two out of four conventional echocardiography criteria were observed: ductal diameter >2 mm, left-right ductal shunt maximum velocity <2 m/sec, mean flow velocity in left pulmonary artery >0." | 2.77 | Echocardiography as a guide for patent ductus arteriosus ibuprofen treatment and efficacy prediction. ( Boubred, F; Desandes, E; Desandes, R; Haddad, F; Hascoët, JM; Jellimann, JM; Rouabah, M; Semama, DS; Vieux, R, 2012) |
| "Ibuprofen levels were detectable 1 h after administration, peaked after 8 h and remained in a relative plateau until 24 h postadministration." | 2.77 | Pharmacokinetics of oral ibuprofen for patent ductus arteriosus closure in preterm infants. ( Baram, S; Barzilay, B; Batash, D; Berkovitch, M; Goldman, M; Heyman, E; Keidar, R; Youngster, I, 2012) |
| "Ibuprofen treatment had no effect on TB, UB, or Ka values." | 2.77 | Unbound bilirubin does not increase during ibuprofen treatment of patent ductus arteriosus in preterm infants. ( Barbier, A; Bordarier, C; Desfrere, L; Kibleur, Y; Moriette, G; Thibaut, C, 2012) |
| "Management of patent ductus arteriosus (PDA) in full-term neonates remains controversial." | 2.75 | Oral ibuprofen and ductus arteriosus closure in full-term neonates: a prospective case-control study. ( Amoozgar, H; Ghodstehrani, M; Pishva, N, 2010) |
| " The template bleeding times before dosing ranged from 135 to 450 s." | 2.74 | Ibuprofen lysine administration to neonates with a patent ductus arteriosus: effect on platelet plug formation assessed by in vivo and in vitro measurements. ( Christensen, RD; Henry, E; Lambert, DK; Schmutz, N; Sheffield, MJ, 2009) |
| "IV ibuprofen was effective and safe in the early closure of PDA in preterm neonates." | 2.74 | A randomized, double-blind, placebo-controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants. ( Aranda, JV; Baggs, G; Carlo, WA; Clyman, R; Cox, B; Darko, L; Seth, A; Shalwitz, R; Sosenko, I; Van Overmeire, B; Ward, RM; Wozniak, P, 2009) |
| "Oral ibuprofen suspension has been shown to have the same efficacy and safety as intravenous indomethacin in the prevention and treatment of symptomatic PDA." | 2.73 | Prophylaxis of symptomatic patent ductus arteriosus with oral ibuprofen in very low birth weight infants. ( Ayudhaya, JK; Kanjanapattanakul, W; Khorana, M; Lertsutthiwong, W; Sangtawesin, C; Sangtawesin, V, 2008) |
| "Ibuprofen has been proposed as a preferential alternative to indomethacin in treating patent ductus arteriosus (PDA), because it is purported to have less renal, mesenteric, and cerebral vasoconstrictive effects." | 2.73 | Ibuprofen versus continuous indomethacin in premature neonates with patent ductus arteriosus: is the difference in the mode of administration? ( Bromiker, R; Hammerman, C; Jacobson, S; Kaplan, M; Nir, A; Schimmel, MS; Shchors, I, 2008) |
| " However, increasing the dosage increases the oxidative stress." | 2.72 | Early closure mechanisms of the ductus arteriosus in immature infants. ( Aikio, O; Hallman, M; Rozé, JC; Treluyer, JM, 2021) |
| "Acetaminophen has emerged as an alternative to indomethacin and ibuprofen with less significant adverse effects, but there is no consensus regarding its use." | 2.72 | Acetaminophen Therapy for Persistent Patent Ductus Arteriosus. ( Amin, S; Manalastas, M; Nicoski, P; Weiss, MG; Zaheer, F, 2021) |
| " Observations collected in two population pharmacokinetic studies, in preterm neonates, investigating amikacin and vancomycin were used to estimate: i) the impact of ibuprofen administration on the clearance of these drugs; and ii) the difference between prophylactic and therapeutic administration of ibuprofen on this clearance." | 2.72 | Impact of ibuprofen administration on renal drug clearance in the first weeks of life. ( Allegaert, K; Anderson, BJ; Rayyan, M, 2006) |
| "Ibuprofen has the same efficiency as indomethacin for the treatment of symptomatic patent ductus arteriosus in preterm infants and less likely to induce necrotizing enterocolitis and renal toxicity than indomethacin." | 2.71 | A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. ( Chotigeat, U; Jirapapa, K; Layangkool, T, 2003) |
| "The occurrence of patent ductus arteriosus was less frequent only on day 3 of life in the ibuprofen group." | 2.71 | Prophylactic ibuprofen for the prevention of intraventricular hemorrhage among preterm infants: a multicenter, randomized study. ( Bertini, G; Dani, C; Guerrini, P; Martano, C; Pezzati, M; Poggi, C; Rubaltelli, FF, 2005) |
| "Ibuprofen has recently been shown to be effective in closing PDA with fewer hemodynamic effects." | 2.71 | [Ibuprofen versus indomethacin in the treatment of patent ductus arteriosus in preterm infants]. ( Cano Sánchez, A; Carrasco Moreno, JI; Fernández Gilino, C; Gimeno Navarro, A; Gutiérrez Laso, A; Izquierdo Macián, I; Morcillo Sopena, F, 2005) |
| "Ibuprofen was not associated with adverse effects." | 2.69 | Prophylaxis of patent ductus arteriosus with ibuprofen in preterm infants. ( Bertini, G; Dani, C; Fabris, C; Murru, P; Reali, MF; Rubaltelli, FF; Vangi, V, 2000) |
| "Ibuprofen treatment significantly reduced plasma levels of prostaglandins, and the levels remained low for 72 hours in newborns who received three doses of the drug." | 2.68 | Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. ( Aranda, JV; Bardin, CL; Beharry, K; Chemtob, S; Papageorgiou, A; Varvarigou, A, 1996) |
| "Ibuprofen treatment seems to be as efficient as indomethacin in closing PDA on the third day of life in preterm infants with respiratory distress syndrome and seems to have fewer renal side effects." | 2.68 | Treatment of patent ductus arteriosus with ibuprofen. ( Creten, WL; Follens, I; Hartmann, S; Van Acker, KJ; Van Overmeire, B, 1997) |
| "Ibuprofen has less effect on blood flow velocity to important organs." | 2.66 | Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. ( Ohlsson, A; Shah, SS, 2020) |
| "A clinically significant patent ductus arteriosus (PDA) is associated with significant morbidity and mortality in premature newborns." | 2.61 | Pre-symptomatic targeted treatment of patent ductus arteriosus in preterm newborns: A systematic review and meta-analysis. ( Abou-Setta, AM; Dingwall, O; Elsayed, YN; Farooqui, MA; Jeyaraman, MM; Rabbani, R; Tagin, M; Zarychanski, R, 2019) |
| " Although promising, acetaminophen treatment requires further studies regarding long-term safety as well as ideal dosing and route of administration." | 2.61 | Pharmacotherapy for patent ductus arteriosus closure. ( Ferguson, JM, 2019) |
| "Ibuprofen has less effect on blood flow velocity to important organs." | 2.61 | Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. ( Ohlsson, A; Shah, SS, 2019) |
| "Oral ibuprofen for closure of the patent ductus arteriosus failed, and the patient exhibited the features of"ventilator dependent"PDA of premature infants." | 2.53 | [Transcatheter occlusion of patent ductus arteriosus in a preterm infant and review of literatures]. ( Hua, Y; Mu, D; Qiao, L; Shi, X; Tang, J; Wang, X; Wang, Y; Zhou, K, 2016) |
| "Ibuprofen appears to be a better choice for PDA closure, with a better side effect profile and efficacy that equals that of indomethacin." | 2.53 | Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration. ( Agarwal, R; Sivanandan, S, 2016) |
| "The clinical management of a patent ductus arteriosus (PDA) in preterm newborns is a controversial topic, and despite nearly three decades of research, varying opinions remain." | 2.53 | Principles of Clinical Management of Patent Ductus Arteriosus in Extremely Preterm Neonates. ( Baral, VR; Tan, ZH, 2016) |
| "Management of the patent ductus arteriosus (PDA) represents an ongoing challenge in the care of extremely premature neonates." | 2.53 | Pharmacotherapy for Patent Ductus Arteriosus: Current Options and Outstanding Questions. ( McPherson, CC; Rostas, SE, 2016) |
| "The patency of the ductus arteriosus is very common in extremely premature infants." | 2.53 | Patent Ductus Arteriosus and Short- and Long-Term Respiratory Outcomes. ( Bancalari, E, 2016) |
| " On the other hand, several adverse effects have been reported with such medications, including peripheral vasoconstriction, gastrointestinal bleeding and perforation, weakened platelet aggregation, hyperbilirubinemia and renal failure." | 2.52 | Safety of therapeutics used in management of patent ductus arteriosus in preterm infants. ( Erdeve, O; Oncel, MY, 2015) |
| "The treatment with ibuprofen reduces the urine output and increases the serum creatinine concentrations less extensively than indomethacin." | 2.50 | Clinical pharmacology of ibuprofen and indomethacin in preterm infants with patent ductus arteriosus. ( Pacifici, GM, 2014) |
| "Pharmacological closure of patent ductus arteriosus (PDA) is commonly achieved by intravenous (IV) administration of ibuprofen or indomethacin." | 2.48 | Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. ( Bührer, C; Neumann, R; Schulzke, SM, 2012) |
| "Ibuprofen has less effect on blood flow velocity to important organs." | 2.47 | Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. ( Ohlsson, A; Shah, SS, 2011) |
| ""Patent ductus arteriosus is one of most common problems that physicians caring for preterm infants have to face." | 2.47 | Patent ductus arteriosus: wait and see? ( Ciarmoli, E; Mosca, F; Schena, F, 2011) |
| "The persistence of a patent ductus arteriosus (PDA) in preterm infants complicates their clinical course and may contribute to increased morbidity." | 2.46 | Efficacy and tolerability of enteral formulations of ibuprofen in the treatment of patent ductus arteriosus in preterm infants. ( Gouyon, JB; Kibleur, Y, 2010) |
| "Indomethacin has long been the drug of choice." | 2.45 | Therapeutic closure of the ductus arteriosus: benefits and limitations. ( Boubred, F; Mercanti, I; Simeoni, U, 2009) |
| "Ibuprofen lysine has demonstrated significantly less effects on cerebral, renal, and mesenteric blood flow in premature neonates when compared with indomethacin." | 2.44 | Ibuprofen lysine for the prevention and treatment of patent ductus arteriosus. ( Pai, VB; Puthoff, TD; Sakadjian, A, 2008) |
| " There is sufficient evidence to consider that ibuprofen, at the currently proposed dosing regimen, has a similar efficacy to indomethacin but is better tolerated by the neonatal kidney when employed for the treatment of established PDA." | 2.44 | Renal effects of ibuprofen for the treatment of patent ductus arteriosus in premature infants. ( Buffat, C; Giniger, RP; Millet, V; Simeoni, U, 2007) |
| "Persistent patent ductus arteriosus (PDA) is a common pathology in the preterm whose traditional treatment has been indomethacin." | 2.44 | [Ibuprofen versus indomethacin in the preterm persistent patent ductus arteriosus therapy: review and meta-analysis]. ( Fernández Gilino, C; Gimeno Navarro, A; Gutiérrez Laso, A; Izquierdo Macián, I; Modesto Alapont, V; Morcillo Sopena, F, 2007) |
| "Ibuprofen treatment was associated with statistically significantly lower serum creatinine levels after treatment (6 trials, 336 infants; WMD - 8." | 2.44 | Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. ( Ohlsson, A; Shah, S; Walia, R, 2008) |
| "Indomethacin has a protective effect on the incidence of intraventricular hemorrhage (IVH) but reduces the blood flow to the kidneys and the brain." | 2.44 | Treatment of patent ductus arteriosus: indomethacin or ibuprofen? ( Corff, KE; Sekar, KC, 2008) |
| "Ibuprofen (IBU) has previously been shown to be as effective as indomethacin (INDO) in closing the patent ductus arteriosus (PDA) of preterm infants, without severely affecting renal hemodynamics or basal cerebral blood flow." | 2.43 | A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. ( Aranda, JV; Parker, GC; Thomas, RL; Van Overmeire, B, 2005) |
| "Ibuprofen has been shown to be effective in closing a PDA without reducing blood flow velocity to the brain, gut or kidneys." | 2.43 | Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. ( Ohlsson, A; Shah, SS, 2006) |
| " The drug has prolonged elimination (plasma half-life = ca 23 hours), suggesting that once daily dosing is appropriate." | 2.43 | Systematic review: intravenous Ibuprofen in preterm newborns. ( Aranda, JV; Thomas, R, 2006) |
| "Indomethacin has long been used to treat patent ductus arteriosus but it is associated with a relatively high risk of adverse effects; recent evidence suggests that ibuprofen is effective and may be safer." | 2.42 | The use of ibuprofen in neonates in the treatment of patent ductus arteriosus. ( Van Overmeire, B, 2003) |
| "Ibuprofen has been shown to be effective in closing a PDA without reducing blood flow velocity to the brain, gut or kidneys." | 2.42 | Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. ( Ohlsson, A; Shah, SS, 2003) |
| " This study explored whether higher concentrations of the biologically active S-enantiomer or increased R- to S-conversion following oral dosing could explain this finding." | 1.91 | Oral Ibuprofen Is More Effective than Intravenous Ibuprofen for Closure of a Patent Ductus Arteriosus: Can Pharmacokinetic Modeling Help Us to Understand Why? ( Engbers, AGJ; Flint, RB; Knibbe, CAJ; Pfister, M; Samiee-Zafarghandy, S; Simons, SHP; Smit, C; van den Anker, JN; van Donge, T, 2023) |
| "Management of persistently patent ductus arteriosus (PDA) in extremely low-birth-weight infants (ELBWIs) requires attention due to the risk of tissue hypoperfusion." | 1.91 | Association between gastrointestinal perforation and patent ductus arteriosus in extremely-low-birth-weight infants: a retrospective study of our decade-long experience. ( Ibara, S; Ieiri, S; Ikee, T; Ikoma, S; Kawano, M; Kawano, T; Machigashira, S; Masuya, R; Matsukubo, M; Murakami, M; Muto, M; Nakame, K; Noguchi, H; Sugita, K; Torikai, M, 2023) |
| "Monitoring patent ductus arteriosus (PDA) in premature infants is currently performed intermittently using echocardiography which requires considerable expertise." | 1.72 | Assessing patent ductus arteriosus in preterm infants from standard neonatal intensive care monitoring. ( Kotidis, C; Rabe, H; Turner, MA; Weindling, M; Wertheim, D, 2022) |
| "What is Known: • Patent ductus arteriosus (PDA) incidence is inversely related to gestational age." | 1.72 | Survey highlighting the lack of consensus on diagnosis and treatment of patent ductus arteriosus in prematurity. ( de Boode, WP; El-Khuffash, A; Hundscheid, T; McNamara, PJ, 2022) |
| "Ibuprofen exposure was based on a previously developed population pharmacokinetic study that was in part based on the same study population." | 1.72 | The Effect of Ibuprofen Exposure and Patient Characteristics on the Closure of the Patent Ductus Arteriosus in Preterm Infants. ( de Klerk, J; Engbers, AGJ; Flint, RB; Goulooze, SC; Knibbe, CAJ; Krekels, EHJ; Reiss, IKM; Simons, SHP; van Dijk, M; Völler, S; Willemsen, SP, 2022) |
| "Indomethacin was used for median (IQR) 3 (2-5) days while ibuprofen was given for 3 (2-4) days, at a median of 8 and 10 days after birth, respectively; surgical treatment was used later at 33 (24-45) days after birth." | 1.72 | Management of patent ductus arteriosus in very preterm infants in England and Wales: a retrospective cohort study. ( Al-Turkait, A; Choonara, I; Ojha, S; Szatkowski, L, 2022) |
| "The presence of patent ductus arteriosus can be as high as 50% in preterm babies." | 1.72 | Percutaneous Closure of Ductus Arteriosus in Preterm Babies: The Initial Brazilian Experience. ( Abujamra, P; Arrieta, R; Coimbra, G; Costa, RND; Cristóvão, SAB; Giuliano, LC; Manica, JLL; Neves, JR; Pedra, C; Rossi Filho, RI; Rossi, JHA; Teixeirense, PT, 2022) |
| "Aspirin treatment during pregnancy seemed to reduce the incidence of hs-PDA in preterm infant and to increase infant responsiveness to postnatal medical treatment of PDA." | 1.72 | Effects of maternal aspirin treatment on hemodynamically significant patent ductus arteriosus in preterm infants - pilot study. ( Beer, G; Fridman, E; Kapusta, L; Mandel, D; Mangel, L; Marom, R, 2022) |
| "Inclusion criteria: patent ductus arteriosus (PDA) with a diameter ≥1 millimeter (mm) at 72 h from birth; need for ibuprofen treatment on the basis of a hemodynamically significant ductus arteriosus (HsPDA)." | 1.62 | Ductal size indexed to weight and body surface area correlates with morbidities in preterm infants ≤32 weeks. ( Brunetti, G; D'Amato, G; Del Vecchio, A; Errico, G; Faienza, MF; Franco, C; Petrillo, F, 2021) |
| "Indomethacin treatment success was defined as: (i) where PDA closed or became haemodynamically insignificant (hisPDA) after treatment and (ii) only including neonates where PDA had complete closure after treatment." | 1.62 | Association between changes in urine output and successful indomethacin treatment for patent ductus arteriosus in preterm neonates. ( Dey, A; Jain, A; Louis, D, 2021) |
| "Presence of a patent ductus arteriosus (PDA) in neonates is assessed by echocardiography." | 1.62 | Ratio of arterial blood pressures at borders of window surrounding systolic peak indicates patent ductus arteriosus in preterm infants. ( Andriessen, P; Bennis, FC; Delhaas, T; Kramer, BW; van Pul, C, 2021) |
| "Use of ibuprofen for the patent ductus arteriosus (PDA) has become increasingly common." | 1.62 | Cost-effectiveness of Oral Versus Intravenous Ibuprofen Therapy in Preterm Infants With Patent Ductus Arteriosus in the Neonatal Intensive Care Setting: A Cohort-based Study. ( Abushanab, D; Al Hail, M; Al-Badriyeh, D; Al-Shaibi, S; Elkassem, W; Kamal, R; Parappil, H; Rouf, PA; Viswanathan, B, 2021) |
| "Drug therapy for pulmonary hypertension is recommended only for those patients who have irreversible pulmonary hypertension." | 1.62 | Comparative Results of Treatment and Complications: Pedea in Open Ductus Arteriosus in Premature Infants. ( Abdrakhmanova, Z; Bekenov, N; Bektenova, G; Datkayeva, G; Gatauova, M; Ilyassova, G; Kemelbekov, K; Khatamov, F; Kuandykov, Y; Musaev, Y; Omarova, B; Tasbulatov, N; Tazhiyeva, A; Tuktibayeva, S; Zhumabekov, Z, 2021) |
| "Ibuprofen (IBU) has been used recently for the treatment of patent ductus arteriosus (PDA) in Japan." | 1.56 | The influence on renal function of ibuprofen treatment for patent ductus arteriosus in extremely low birthweight infants. ( Matsuda, A; Nishizaki, N; Obinata, K; Shimizu, T; Watanabe, A; Yoneyama, T, 2020) |
| "Persistent patent ductus arteriosus (PDA) in preterm infants is associated with increased mortality and respiratory morbidities, including bronchopulmonary dysplasia (BPD)." | 1.56 | Effect of Nonintervention vs Oral Ibuprofen in Patent Ductus Arteriosus in Preterm Infants: A Randomized Clinical Trial. ( Ahn, SY; Chang, YS; Lee, MH; Park, WS; Sung, SI, 2020) |
| "Ibuprofen treatment increases the risk for death in preterm infants with NEC." | 1.51 | [Clinical features and outcomes of neonatal necrotizing enterocolitis]. ( Gan, X; Li, J; Mao, J, 2019) |
| "ibuprofen treatment and gestational age of 23-24 versus 25-28 weeks increased closure failure, while less severe RDS and maternal clinical chorioamnionitis decreased it." | 1.51 | Patent ductus arteriosus in preterm infants born at 23-24 weeks' gestation: Should we pay more attention? ( Boni, L; Capasso, L; Corvaglia, L; Cresi, F; Dani, C; Del Vecchio, A; Fanos, V; Laforgia, N; Lago, P; Lista, G; Maffei, G; Mosca, F; Paolillo, P; Trevisanuto, D, 2019) |
| " High dosage ibuprofen was associated with a faster clinical improvement and higher rate of PDA closure." | 1.51 | Oral ibuprofen is superior to oral paracetamol for patent ductus arteriosus in very low and extremely low birth weight infants. ( Chen, C; Li, Q; Li, Z; Lu, J; Zhu, L, 2019) |
| "Ibuprofen was chemically stable with all PN and SMOF lipid admixture, for a period of 4 hours." | 1.48 | Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion. ( Andersen, C; Fotios, A; Garcia, J; Garg, A; Garg, S; Song, Y, 2018) |
| " We aimed to propose an improved dosing regimen, based on all current knowledge." | 1.48 | Simulation-based suggestions to improve ibuprofen dosing for patent ductus arteriosus in preterm newborns. ( Allegaert, K; Burger, DM; de Klerk, JCA; Flint, RB; Knibbe, CAJ; Simons, SHP; Spaans, E; Ter Heine, R, 2018) |
| "Patent ductus arteriosus is a common problem frequently encountered in preterm infants." | 1.48 | Reopening of the ductus arteriosus in preterm infants; Clinical aspects and subsequent consequences. ( Atay, FY; Buyuktiryaki, M; Halil, H; Oncel, MY; Uras, N, 2018) |
| "To evaluate whether the presence of patent ductus arteriosus (PDA) in preterm infants worsens long-term neurodevelopmental outcomes." | 1.48 | Long-Term Neurodevelopment of Low-Birthweight, Preterm Infants with Patent Ductus Arteriosus. ( Casey, PH; Collins, RT; Gossett, JM; Lyle, RE; Rettiganti, M; Robbins, JM, 2018) |
| " All four participating neonatal ICU had a comparable number of preterm infants; however, differences were observed in the incidence of treatment (33-63%), choice and dosing of medication (ibuprofen or indomethacin), number of pharmacological courses (1-4), and the need for surgical ligation after failure of pharmacological treatment (8-52%)." | 1.46 | Using benchmarking to identify inter-centre differences in persistent ductus arteriosus treatment: can we improve outcome? ( Andriessen, P; de Boode, WP; de Vries, WB; Dijkman, KP; Jansen, EJS; van Lingen, RA; Vijlbrief, DC, 2017) |
| "The symptomatic patent ductus arteriosus (sPDA) is common in extremely premature infants (EPI)." | 1.46 | [Digestive and Kidney Complications by indomethacin and ibuprofen in extreme preterm infants with patent ductus arteriosus]. ( Lavín, P; López, M; Miranda, J; Rincón, Y; Salas, R, 2017) |
| "To examine yearly trends of patent ductus arteriosus (PDA) diagnosis and treatment in very low birth weight infants." | 1.46 | Trends in Patent Ductus Arteriosus Diagnosis and Management for Very Low Birth Weight Infants. ( Gould, JB; Lee, HC; Ngo, S; Profit, J, 2017) |
| " This study aimed to describe patent ductus arteriosus (PDA) closure rates and adverse events after repeated courses of OIBU in premature infants with PDA." | 1.46 | Repeated Courses of Oral Ibuprofen in Premature Infants with Patent Ductus Arteriosus: Efficacy and Safety. ( Becit, N; Caner, İ; Ceviz, N; Karacan, M; Kartal, İ; Olgun, H; Taştekin, A, 2017) |
| "Although the frequency of secondary patent ductus arteriosus (PDA) ligation and the incidence of bronchopulmonary dysplasia (BPD) was higher in the clinical symptoms group in the univariate analysis, after multivariate logistic regression analysis adjusting for the CRIB-II score, birthweight, birth year, and the invasive ventilator care ≤ 2 postnatal days, there were no significant differences in mortality, frequency of secondary ligation and in-hospital outcomes including necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), BPD or death." | 1.46 | Comparison of the Mortality and In-Hospital Outcomes of Preterm Infants Treated with Ibuprofen for Patent Ductus Arteriosus with or without Clinical Symptoms Attributable to the Patent Ductus Arteriosus at the Time of Ibuprofen Treatment. ( Choi, CW; Jung, YH; Kim, BI; Kim, EK; Kim, HS; Lee, JA; Oh, S; Shin, SH; Sohn, JA; Yoo, H, 2017) |
| "Treatment of the patent ductus arteriosus (PDA) in the preterm infant remains contentious." | 1.46 | A conservative treatment of patent ductus arteriosus in very low birth weight infants. ( Dempsey, EM; Franklin, OM; Letshwiti, JB; Miletin, J; Pichova, K; Semberova, J, 2017) |
| "Management of patent ductus arteriosus (PDA) in preterm infants is one of the most controversial topics in neonatal medicine." | 1.43 | Effectiveness and safety of treatments used for the management of patent ductus arteriosus (PDA) in preterm infants: a protocol for a systematic review and network meta-analysis. ( Aune, D; Florez, ID; Mbuagbaw, L; Mitra, S; Tamayo, ME; Thabane, L; Veroniki, AA, 2016) |
| "Indomethacin was more efficacious for ductal closure although did not impact outcomes." | 1.42 | Indomethacin vs ibuprofen: comparison of efficacy in the setting of conservative therapeutic approach. ( Malikiwi, A; Roufaeil, C; Sehgal, A; Tan, K, 2015) |
| "The optimal timing of pharmacological treatment for patent ductus arteriosus (PDA) in extremely preterm infants is unknown." | 1.42 | Timing of pharmacological treatment for patent ductus arteriosus and risk of secondary surgery, death or bronchopulmonary dysplasia: a population-based cohort study of extremely preterm infants. ( Bonamy, AK; Gudmundsdottir, A; Håkansson, S; Johansson, S; Källen, K; Norman, M, 2015) |
| "Finding the optimal pharmacological treatment of a patent ductus arteriosus (PDA) in preterm neonates remains challenging." | 1.42 | Limited effects of intravenous paracetamol on patent ductus arteriosus in very low birth weight infants with contraindications for ibuprofen or after ibuprofen failure. ( de Klerk, JC; Reiss, IK; Roofthooft, DW; Simons, SH; Tibboel, D; van Beynum, IM; van den Anker, JN; van Dijk, M, 2015) |
| "And ibuprofen treatment did not negatively influence renal and mesenteric oxygenation and extraction in infants with PDA (p > 0." | 1.40 | Renal and mesenteric tissue oxygenation in preterm infants treated with oral ibuprofen. ( Altug, N; Dilmen, U; Guzoglu, N; Oguz, SS; Ozdemir, R; Sari, FN; Uras, N, 2014) |
| "Ibuprofen treatment was administered to patients with patent ductus arteriosus." | 1.40 | "Shunt index" can be used to predict clinically significant patent ductus arteriosus in premature neonates in early post-natal life. ( Ecevit, A; Gökdemir, M; Gülcan, H; Ince, DA; Tarcan, A; Törer, B; Yapakçı, E, 2014) |
| "Ibuprofen treatment was given to 15 paracetamol-treated and to 26 control infants (p = 0." | 1.40 | Early paracetamol treatment associated with lowered risk of persistent ductus arteriosus in very preterm infants. ( Aikio, O; Hallman, M; Härkin, P; Saarela, T, 2014) |
| "Hemodynamically significant patent ductus arteriosus (hsPDA) leads to injury in tissues/organs by reducing perfusion of organs and causing oxidative stress." | 1.40 | Impact of patent ductus arteriosus and subsequent therapy with ibuprofen on the release of S-100B and oxidative stress index in preterm infants. ( Balahoroğlu, R; Demir, N; Ece, İ; Kaba, S; Peker, E; Tuncer, O; Ustyol, L, 2014) |
| "Presence of symptomatic patent ductus arteriosus is common in small preterm infants and ibuprofen is commonly used for its medical closure." | 1.39 | Pulmonary hypertension in an infant treated with ibuprofen. ( Kumarshingri, PS; Sehgal, A, 2013) |
| "Hemodynamically significant patent ductus arteriosus (hsPDA) complicates the clinical course of preterm infants and contributes to increased morbidity and mortality." | 1.39 | Elevated urinary NT-proBNP after pharmacological closure of patent ductus arteriosus in very low birth weight infants. ( Canpolat, FE; Celik, IH; Demırel, G; Dilmen, U; Erdeve, O, 2013) |
| "Course of sepsis was evaluated by CRP and IL-6 levels." | 1.38 | The effects of ibuprofen on sepsis parameters in preterm neonates. ( Canpolat, FE; Celik, IH; Demirel, G; Dilmen, U; Erdeve, O; Oguz, SS, 2012) |
| "The effect of patent ductus arteriosus (PDA) treatment with cyclooxygenase (COX) inhibitors (indomethacin [INDO] and ibuprofen [IBU]) on regional oxygenation requires further clarification." | 1.38 | Does treatment of patent ductus arteriosus with cyclooxygenase inhibitors affect neonatal regional tissue oxygenation? ( Bhatt, M; Mehta, R; Petrova, A, 2012) |
| "Pulmonary hypertension is a rare but potentially fatal complication of ibuprofen administration in preterm infants." | 1.38 | Severe pulmonary hypertension with therapeutic L-lysine ibuprofen in 2 preterm neonates. ( Aghai, ZH; Amendolia, B; Bhat, V; Lynn, M; Ritz, SB, 2012) |
| "Persistent patency of the ductus arteriosus is a major cause of morbidity and mortality in premature infants." | 1.38 | Patent ductus arteriosus in premature neonates. ( Agarwal, G; Maheshwari, A; Mezu-Ndubuisi, OJ; Ohler, KH; Pham, JT; Raghavan, A, 2012) |
| " The explanation of the reduced pharmacodymanic effect in such population is unclear; so far, studies using increased dosing of ibuprofen have failed to show a clear benefit." | 1.38 | Ibubrofen in the treatment of patent ductus arteriosus in preterm infants: what we know, what we still do not know. ( Boubred, F; Buffat, C; Fayol, L; Grandvuillemin, I; Ligi, I; Mercanti, I; Millet, V; Simeoni, U, 2012) |
| "Ibuprofen-treatment has no effect on the expression of genes that regulate pulmonary inflammation but does increase the expression of alpha-ENaC (the transepithelial sodium channel that is critical for alveolar water clearance)." | 1.37 | Patent ductus arteriosus ligation alters pulmonary gene expression in preterm baboons. ( Clyman, RI; McCurnin, DC; Shaul, PW; Waleh, N; Yoder, BA, 2011) |
| "In ibuprofen group, there was no correlation of AQP2 level with urinary osmolality." | 1.37 | Urinary aquaporin-2 excretion during ibuprofen or indomethacin treatment in preterm infants with patent ductus arteriosus. ( Aperia, A; Casper, C; Li, Y; Marcoux, MO; Plat-Willson, G; Zelenina, M, 2011) |
| "The clinical decision to treat the patent ductus arteriosus is complicated by the lack of evidence available regarding clinical conditions under which closure should be attempted." | 1.37 | Treatment of patent ductus arteriosus with bidirectional flow in neonates. ( Cotten, CM; Ethington, PN; Goldberg, RN; Katakam, L; Smith, PB, 2011) |
| "Ibuprofen treatment of patent ductus arteriosus (PDA) has been shown to be as effective as indomethacin in small randomized controlled trials, with possibly fewer adverse effects." | 1.37 | Comparison of renal effects of ibuprofen versus indomethacin during treatment of patent ductus arteriosus in contiguous historical cohorts. ( Kushnir, A; Pinheiro, JM, 2011) |
| "Treatment with ibuprofen is safer, decreasing the risk of renal failure, thrombocytopenia, and hyponatremia." | 1.36 | Treatment of patent ductus arteriosus: indomethacin or ibuprofen? ( Bello, R; Birk, E; Hernandez, A; Klinger, G; Linder, N; Pushkov, Y; Rosen, C; Sirota, L, 2010) |
| "Ibuprofen treatment for PDA closure in the preterm baboon neonate is not associated with any increased risk of neuropathology or alterations to brain growth and development." | 1.36 | Ibuprofen treatment for closure of patent ductus arteriosus is not associated with increased risk of neuropathology. ( Clyman, RI; Inder, TE; Loeliger, M; McCurnin, D; Rees, SM; Shields, A; Yoder, B, 2010) |
| "CYP2C polymorphism was not associated with PDA response to ibuprofen and this factor appears not appropriate to optimize the ductal closure rate by modulating ibuprofen dosing strategy." | 1.36 | Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants? ( Alberti, C; Aujard, Y; Barre, J; Baud, O; Danan, C; Decobert, F; Durrmeyer, X; Hovhannisyan, S; Jacqz-Aigrain, E; Médard, Y, 2010) |
| "Lower GA (P<0." | 1.35 | Factors affecting postnatal changes in serum creatinine in preterm infants with gestational age <32 weeks. ( Bonsante, F; Ferdinus, C; Gouyon, JB; Iacobelli, S; Labenne, M, 2009) |
| "Indomethacin is used to close the patent ductus arteriosus in premature infants and for tocolysis of preterm labor." | 1.35 | Delayed neonatal closure of the ductus arteriosus following early in utero exposure to indomethacin in the rat. ( Imamura, S; Ito, K; Momma, K; Nakanishi, T; Sugiyama, K; Sun, F; Toyoshima, K, 2009) |
| "Ibuprofen has been shown to be as effective as indomethacin with fewer renal side effects." | 1.35 | Early postnatal ibuprofen and indomethacin effects in suckling and weanling rat kidneys. ( Abad-Santos, M; Abad-Santos, P; Aranda, JV; Beharry, KD; Gharraee, Z; Hasan, J; Modanlou, HD; Stavitsky, Y, 2008) |
| "Ibuprofen is a nonsteroidal anti-inflammatory agent that induces closure of the patent ductus arteriosus in neonates." | 1.35 | An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. ( Eisinger, MJ; Hirt, D; Langhendries, JP; Marguglio, A; Schepens, P; Treluyer, JM; Urien, S; Van Overmeire, B, 2008) |
| "Ibuprofen-induced patent ductus arteriosus closure improved pulmonary mechanics, decreased total lung water, increased epithelial sodium channel expression, and decreased the detrimental effects of preterm birth on alveolarization." | 1.35 | Ibuprofen-induced patent ductus arteriosus closure: physiologic, histologic, and biochemical effects on the premature lung. ( Albertine, KH; Chang, LY; Clyman, RI; Dahl, MJ; Giavedoni, L; Ikegami, M; McCurnin, D; Petershack, J; Seidner, S; Waleh, N; Wang, ZM; Yoder, B, 2008) |
| "Indomethacin is commonly used for the treatment of patent ductus arteriosus (PDA) but has renal failure as a main side-effect." | 1.33 | Efficacy and renal tolerability of ibuprofen vs. indomethacin in preterm infants with patent ductus arteriosus. ( Benini, D; Cuzzolin, L; Errico, G; Fanos, V; Verlato, G, 2005) |
| "Ibuprofen treatment caused a significant decrease in urinary AVP (UAVP/Ucr 24." | 1.33 | Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus. ( Faggian, D; Favaro, F; Lago, P; Plebani, M; Trevisanuto, D; Vedovato, S; Zanardo, V, 2005) |
| " Kinetic analyses assumed applicability of one open-compartment model and calculations from the model-independent areas under the time concentration curve (AUC)." | 1.30 | Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. ( Aranda, JV; Bansal, R; Bardin, C; Beharry, K; Chemtob, S; Modanlou, H; Papageorgiou, A; Varvarigou, A, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (0.73) | 18.7374 |
| 1990's | 9 (2.19) | 18.2507 |
| 2000's | 85 (20.68) | 29.6817 |
| 2010's | 206 (50.12) | 24.3611 |
| 2020's | 108 (26.28) | 2.80 |
| Authors | Studies |
|---|---|
| Hundscheid, T | 6 |
| Donders, R | 4 |
| Onland, W | 4 |
| Kooi, EMW | 4 |
| Vijlbrief, DC | 6 |
| de Vries, WB | 4 |
| Nuytemans, DHGM | 3 |
| van Overmeire, B | 12 |
| Mulder, AL | 3 |
| de Boode, WP | 9 |
| Noori, S | 2 |
| Seri, I | 1 |
| Silahli, M | 1 |
| Gokmen, Z | 1 |
| Tekin, M | 1 |
| Wu, JJ | 1 |
| Niduvaje, K | 1 |
| Lee, LY | 1 |
| Amin, Z | 1 |
| Kotidis, C | 1 |
| Wertheim, D | 1 |
| Weindling, M | 1 |
| Rabe, H | 1 |
| Turner, MA | 1 |
| Bin-Nun, A | 3 |
| Abu-Omar, R | 2 |
| Shchors, I | 3 |
| Mimouni, F | 2 |
| Hammerman, C | 8 |
| Gover, A | 1 |
| Levy, PT | 2 |
| Rotschild, A | 1 |
| Golzman, M | 1 |
| Molad, M | 1 |
| Lavie-Nevo, K | 1 |
| Kessel, I | 2 |
| Cakir, U | 2 |
| Tayman, C | 3 |
| Katsaras, DN | 1 |
| Katsaras, GN | 1 |
| Chatziravdeli, VI | 1 |
| Papavasileiou, GN | 1 |
| Touloupaki, M | 1 |
| Mitsiakos, G | 1 |
| Doxani, C | 1 |
| Stefanidis, I | 1 |
| Dardiotis, E | 1 |
| Vidavalur, R | 1 |
| El-Khuffash, A | 5 |
| McNamara, PJ | 5 |
| Yurttutan, S | 11 |
| Abdaljalil, H | 1 |
| Nitzan, I | 1 |
| Kasirer, Y | 1 |
| Schorrs, I | 1 |
| Yeung, T | 1 |
| Shahroor, M | 1 |
| Jain, A | 5 |
| Weisz, D | 2 |
| Jasani, B | 6 |
| Engbers, AGJ | 3 |
| Völler, S | 1 |
| Flint, RB | 4 |
| Goulooze, SC | 1 |
| de Klerk, J | 1 |
| Krekels, EHJ | 2 |
| van Dijk, M | 2 |
| Willemsen, SP | 1 |
| Reiss, IKM | 1 |
| Knibbe, CAJ | 5 |
| Simons, SHP | 4 |
| Raghu, K | 1 |
| Berry, MJ | 1 |
| Bauer-Rusek, S | 1 |
| Samra, N | 1 |
| Moore, SS | 1 |
| Arnon, S | 1 |
| Balasubramanian, H | 1 |
| Jain, V | 1 |
| Bhalgat, P | 1 |
| Parikh, S | 1 |
| Kabra, N | 1 |
| Mohan, D | 1 |
| Sheth, K | 1 |
| Kim, CY | 1 |
| Chung, SH | 1 |
| Kwan, R | 1 |
| Vasanwala, RF | 1 |
| Baral, VR | 2 |
| Shah, SD | 1 |
| Makker, K | 1 |
| Zhang, M | 2 |
| Harnett, S | 1 |
| Aziz, KB | 1 |
| Hudak, ML | 1 |
| Al-Turkait, A | 1 |
| Szatkowski, L | 1 |
| Choonara, I | 1 |
| Ojha, S | 1 |
| Manica, JLL | 1 |
| Neves, JR | 1 |
| Arrieta, R | 1 |
| Abujamra, P | 1 |
| Rossi Filho, RI | 1 |
| Giuliano, LC | 1 |
| Coimbra, G | 1 |
| Teixeirense, PT | 1 |
| Rossi, JHA | 1 |
| Costa, RND | 1 |
| Cristóvão, SAB | 1 |
| Pedra, C | 1 |
| Olowoyeye, A | 3 |
| Nnamdi-Nwosu, O | 3 |
| Manalastas, M | 4 |
| Okwundu, C | 3 |
| Deveci, MF | 2 |
| Kaya, H | 2 |
| Alagoz, M | 2 |
| Gokce, IK | 2 |
| Karakurt, C | 2 |
| Gullu, UU | 4 |
| Oncul, M | 2 |
| Ozdemir, R | 7 |
| Dijkman, KP | 4 |
| van Kaam, AH | 3 |
| Villamor, E | 4 |
| Kroon, AA | 3 |
| Visser, R | 3 |
| Mulder-de Tollenaer, SM | 2 |
| De Bisschop, B | 2 |
| Dijk, PH | 2 |
| Avino, D | 2 |
| Hocq, C | 3 |
| Zecic, A | 3 |
| Meeus, M | 2 |
| de Baat, T | 2 |
| Derriks, F | 2 |
| Henriksen, TB | 2 |
| Kyng, KJ | 2 |
| Smit, C | 3 |
| Samiee-Zafarghandy, S | 4 |
| van Donge, T | 3 |
| Pfister, M | 3 |
| van den Anker, JN | 3 |
| Mitra, S | 10 |
| Shah, PS | 7 |
| Kaur, S | 2 |
| Manerkar, S | 1 |
| Mondkar, J | 1 |
| Kalamdani, P | 1 |
| Patra, S | 1 |
| Kalathingal, T | 1 |
| Utsumi, M | 1 |
| Motoki, N | 1 |
| Yokota, S | 1 |
| Kobayashi, H | 1 |
| Yamazaki, S | 1 |
| Miyosawa, Y | 1 |
| Muto, M | 1 |
| Sugita, K | 1 |
| Murakami, M | 1 |
| Ikoma, S | 1 |
| Kawano, M | 1 |
| Masuya, R | 1 |
| Matsukubo, M | 1 |
| Kawano, T | 1 |
| Machigashira, S | 1 |
| Nakame, K | 1 |
| Torikai, M | 1 |
| Ikee, T | 1 |
| Noguchi, H | 1 |
| Ibara, S | 1 |
| Ieiri, S | 1 |
| de Waal, K | 1 |
| Crendal, E | 1 |
| Poon, AC | 1 |
| Latheef, MS | 1 |
| Sachawars, E | 1 |
| MacDougall, T | 1 |
| Phad, N | 1 |
| Hatfield, T | 2 |
| Campbell-Yeo, M | 1 |
| Dorling, J | 2 |
| Johnston, BC | 1 |
| Borges-Luján, M | 1 |
| González-Luis, G | 1 |
| Weisz, DE | 2 |
| Reese, J | 5 |
| Sallmon, H | 4 |
| Delaney, CA | 1 |
| Zhang, Z | 1 |
| Lou, X | 1 |
| Hua, L | 1 |
| Jia, X | 1 |
| Xu, L | 1 |
| Zhao, M | 1 |
| Namba, F | 2 |
| Honda, M | 1 |
| Sakatani, S | 1 |
| Motojima, Y | 1 |
| Kikuchi, K | 1 |
| Sako, M | 1 |
| Ogawa, K | 1 |
| Mikami, M | 1 |
| Kawada, K | 1 |
| Fukuoka, N | 1 |
| Ueda, K | 1 |
| Al-Shaibi, S | 2 |
| Abushanab, D | 2 |
| Abounahia, F | 1 |
| Awaisu, A | 1 |
| Al-Badriyeh, D | 2 |
| Höck, M | 1 |
| Sappler, M | 1 |
| Hammerl, M | 1 |
| Griesmaier, E | 1 |
| Ndayisaba, JP | 1 |
| Schreiner, C | 1 |
| Pupp-Peglow, U | 1 |
| Kiechl-Kohlendorfer, U | 1 |
| Neubauer, V | 1 |
| Elena, I | 1 |
| Daniela, D | 1 |
| Wright, CJ | 4 |
| McCulley, DJ | 1 |
| Jensen, EA | 1 |
| van den Anker, J | 2 |
| Zhong, B | 1 |
| Tan, K | 3 |
| Razak, A | 3 |
| Sackett, V | 1 |
| Machipisa, C | 1 |
| Zhou, L | 1 |
| Sehgal, A | 4 |
| Hunt, RW | 1 |
| Pharande, P | 2 |
| Malhotra, A | 1 |
| Carneiro, L | 1 |
| Bouissou, A | 1 |
| Favrais, G | 2 |
| Kumar, A | 2 |
| Dutta, S | 2 |
| Gupta, N | 1 |
| Khalil, S | 1 |
| Xiao, D | 1 |
| Jin, Y | 1 |
| Di, X | 1 |
| Fu, L | 1 |
| Jiang, C | 1 |
| Lai, Z | 1 |
| Ge, Y | 1 |
| Ji, S | 1 |
| Zhang, Y | 2 |
| Zheng, L | 1 |
| Wang, Z | 1 |
| Gong, F | 1 |
| Cheema, HA | 1 |
| Majeed, Z | 1 |
| Hayat, T | 1 |
| Ahmed, A | 1 |
| Tariq, MH | 1 |
| Shahid, A | 1 |
| Titus, A | 1 |
| Minhas, AMK | 1 |
| Ijaz, SH | 1 |
| Ghelani, SJ | 1 |
| Kulkarni, A | 1 |
| Dani, SS | 1 |
| Chen, X | 1 |
| Qiu, X | 1 |
| Sun, P | 1 |
| Lin, Y | 1 |
| Huang, Z | 1 |
| Yang, C | 1 |
| Walther, FJ | 3 |
| Jensen, TB | 1 |
| Kampmann, JP | 1 |
| Trærup Andersen, J | 1 |
| Aldecoa-Bilbao, V | 1 |
| García-Catalán, MJ | 1 |
| Gaixa, M | 1 |
| Clotet Caba, J | 1 |
| Teodoro, S | 1 |
| Figaró Voltà, C | 1 |
| D'Amato, G | 1 |
| Errico, G | 2 |
| Franco, C | 1 |
| Brunetti, G | 1 |
| Petrillo, F | 1 |
| Faienza, MF | 1 |
| Del Vecchio, A | 2 |
| Gan, X | 1 |
| Mao, J | 2 |
| Li, J | 1 |
| Nishizaki, N | 1 |
| Matsuda, A | 1 |
| Yoneyama, T | 1 |
| Watanabe, A | 1 |
| Obinata, K | 1 |
| Shimizu, T | 1 |
| Xiong, T | 1 |
| Maheshwari, A | 2 |
| Neu, J | 1 |
| Ei-Saie, A | 1 |
| Pammi, M | 1 |
| Martini, S | 1 |
| Aceti, A | 1 |
| Galletti, S | 1 |
| Beghetti, I | 1 |
| Faldella, G | 1 |
| Corvaglia, L | 2 |
| Ohlsson, A | 15 |
| Shah, SS | 8 |
| Fridman, E | 1 |
| Mangel, L | 1 |
| Mandel, D | 1 |
| Beer, G | 1 |
| Kapusta, L | 1 |
| Marom, R | 2 |
| Isayama, T | 1 |
| Kusuda, S | 1 |
| Reichman, B | 1 |
| Lee, SK | 1 |
| Lehtonen, L | 1 |
| Norman, M | 3 |
| Adams, M | 1 |
| Bassler, D | 1 |
| Helenius, K | 1 |
| Hakansson, S | 5 |
| Yang, J | 1 |
| Oh, SH | 1 |
| Lee, BS | 1 |
| Jung, E | 1 |
| Oh, MY | 1 |
| Do, HJ | 1 |
| Kim, EA | 1 |
| Kim, KS | 1 |
| Noureldein, M | 1 |
| Hu, K | 1 |
| Groucutt, J | 1 |
| Heaver, R | 1 |
| Gurusamy, K | 1 |
| Gosavi, RS | 1 |
| Sundaram, V | 1 |
| Oleti, TP | 1 |
| Krishnan, A | 1 |
| Kiran, S | 1 |
| Kumar, J | 3 |
| Murki, S | 1 |
| Sundaram, M | 1 |
| Saini, SS | 1 |
| Hills, NK | 1 |
| Clyman, R | 5 |
| Aikio, O | 3 |
| Juujärvi, S | 1 |
| Saarela, T | 2 |
| Hallman, M | 3 |
| Davidson, JM | 1 |
| Ferguson, J | 1 |
| Ivey, E | 1 |
| Philip, R | 1 |
| Weems, MF | 1 |
| Talati, AJ | 1 |
| Ghirardello, S | 1 |
| Raffaeli, G | 1 |
| Crippa, BL | 1 |
| Gulden, S | 1 |
| Amodeo, I | 1 |
| Consonni, D | 1 |
| Cavallaro, G | 1 |
| Schena, F | 5 |
| Mosca, F | 10 |
| Sung, SI | 2 |
| Lee, MH | 2 |
| Ahn, SY | 1 |
| Chang, YS | 1 |
| Park, WS | 2 |
| Tuteja, A | 1 |
| Pournami, F | 1 |
| Kolisambeevi, AA | 1 |
| Nandakumar, A | 1 |
| Prabhakar, J | 1 |
| Jain, N | 1 |
| Shen, X | 1 |
| Huang, Y | 1 |
| Guo, H | 1 |
| Peng, H | 1 |
| Yao, S | 1 |
| Zhou, M | 1 |
| Liu, H | 1 |
| Lin, HC | 2 |
| Zhou, P | 1 |
| Iacobelli, S | 2 |
| Lorrain, S | 1 |
| Gouyon, B | 1 |
| Gambacorta, S | 1 |
| Laforgia, N | 2 |
| Gouyon, JB | 3 |
| Bonsante, F | 2 |
| Marissen, J | 1 |
| Erdmann, H | 1 |
| Böckenholt, K | 1 |
| Hoppenz, M | 1 |
| Rausch, TK | 1 |
| Härtel, C | 1 |
| Herting, E | 1 |
| Göpel, W | 1 |
| Dani, C | 11 |
| Lista, G | 3 |
| Bianchi, S | 1 |
| Ramenghi, L | 3 |
| Zecca, E | 3 |
| Vento, G | 1 |
| Poggi, C | 5 |
| Leonardi, V | 1 |
| Minghetti, D | 1 |
| Rosignoli, MT | 2 |
| Calisti, F | 1 |
| Comandini, A | 2 |
| Cattaneo, A | 1 |
| Lipone, P | 2 |
| Oboodi, R | 1 |
| Najib, KS | 1 |
| Amoozgar, H | 3 |
| Pourarian, S | 2 |
| Moghtaderi, M | 1 |
| Mehdizadegan, N | 1 |
| Sabzevari, F | 1 |
| Karacaglar, NB | 1 |
| Beser, E | 1 |
| Ceran, B | 1 |
| Unsal, H | 2 |
| Ndour, D | 1 |
| Bouamari, H | 1 |
| Berthiller, J | 1 |
| Claris, O | 1 |
| Plaisant, F | 1 |
| Nguyen, KA | 1 |
| Bussmann, N | 3 |
| Breatnach, CR | 2 |
| Smith, A | 2 |
| Tully, E | 1 |
| Griffin, J | 1 |
| McCallion, N | 2 |
| Corcoran, JD | 1 |
| Fernandez, E | 2 |
| Looi, C | 1 |
| Cleary, B | 2 |
| Franklin, O | 2 |
| Louis, D | 2 |
| Dey, A | 1 |
| Faim, DRO | 1 |
| Tiago, JAM | 1 |
| Castelo, RJS | 1 |
| Francisco, ASS | 1 |
| Alves, RR | 1 |
| Pires, AMGS | 1 |
| El Manouni El Hassani, S | 1 |
| Niemarkt, HJ | 1 |
| Derikx, JPM | 1 |
| Berkhout, DJC | 1 |
| Ballón, AE | 1 |
| de Graaf, M | 1 |
| Cossey, V | 1 |
| Hulzebos, CV | 1 |
| Kramer, BW | 2 |
| van Lingen, RA | 2 |
| van Weissenbruch, MM | 1 |
| Benninga, MA | 1 |
| de Boer, NKH | 1 |
| de Meij, TGJ | 1 |
| Matsumura, S | 1 |
| Masutani, S | 1 |
| Oshima, A | 1 |
| Kanai, M | 1 |
| Ishiguro, A | 1 |
| Kabe, K | 1 |
| Scrivens, A | 1 |
| von Kursell, AM | 1 |
| Disher, T | 1 |
| Rozé, JC | 5 |
| Cambonie, G | 1 |
| Le Thuaut, A | 1 |
| Debillon, T | 1 |
| Ligi, I | 2 |
| Gascoin, G | 3 |
| Patkai, J | 2 |
| Beuchee, A | 1 |
| Flamant, C | 2 |
| Durrmeyer, X | 2 |
| Bennis, FC | 1 |
| Andriessen, P | 2 |
| van Pul, C | 1 |
| Delhaas, T | 1 |
| Ye, C | 1 |
| Lyu, Q | 1 |
| Jiang, L | 1 |
| Yu, L | 1 |
| Xu, Y | 1 |
| Zhang, J | 1 |
| Lu, X | 1 |
| Rouf, PA | 1 |
| Al Hail, M | 1 |
| Kamal, R | 1 |
| Viswanathan, B | 1 |
| Parappil, H | 1 |
| Elkassem, W | 1 |
| Joye, S | 1 |
| Giesinger, RE | 1 |
| Tolsa, JF | 1 |
| Sekarski, N | 1 |
| Gupta, S | 4 |
| Juszczak, E | 2 |
| Hardy, P | 2 |
| Subhedar, N | 1 |
| Wyllie, J | 1 |
| Kelsall, W | 1 |
| Sinha, S | 1 |
| Johnson, S | 1 |
| Roberts, T | 1 |
| Hutchison, E | 1 |
| Pepperell, J | 1 |
| Linsell, L | 2 |
| Bell, JL | 2 |
| Stanbury, K | 1 |
| Laube, M | 1 |
| Edwards, C | 1 |
| Field, D | 1 |
| Treluyer, JM | 3 |
| Parker, LA | 1 |
| Desorcy-Scherer, K | 1 |
| Magalhães, M | 1 |
| Hillier, K | 1 |
| Jones, K | 1 |
| MacInnis, M | 1 |
| Schindler, T | 1 |
| Smyth, J | 1 |
| Bolisetty, S | 1 |
| Michalowski, J | 1 |
| Mallitt, KA | 1 |
| Singla, A | 1 |
| Lui, K | 1 |
| Zaheer, F | 1 |
| Nicoski, P | 1 |
| Weiss, MG | 1 |
| Amin, S | 1 |
| Ting, JY | 1 |
| Ben Fadel, N | 1 |
| Drolet, C | 1 |
| Abou Mehrem, A | 1 |
| Soraisham, A | 1 |
| Lapointe, A | 1 |
| Khurshid, F | 1 |
| Hyderi, A | 1 |
| Kumaran, K | 1 |
| Bodani, J | 1 |
| Alvaro, R | 1 |
| Adie, M | 1 |
| Stavel, M | 1 |
| Morin, A | 1 |
| Bhattacharya, S | 1 |
| Kanungo, J | 1 |
| Canning, R | 1 |
| Ye, XY | 1 |
| Gardner, CE | 1 |
| Shah, P | 1 |
| Fusch, G | 1 |
| Jacob, G | 1 |
| Atkinson, A | 1 |
| Rieder, MJ | 1 |
| Angelis, D | 1 |
| Jagarapu, J | 1 |
| Wan-Huen, P | 1 |
| Savani, RC | 1 |
| Jaleel, M | 1 |
| Abbas, A | 1 |
| Cawsey, M | 1 |
| Kemelbekov, K | 1 |
| Musaev, Y | 1 |
| Bektenova, G | 1 |
| Datkayeva, G | 1 |
| Tuktibayeva, S | 1 |
| Bekenov, N | 1 |
| Khatamov, F | 1 |
| Ilyassova, G | 1 |
| Gatauova, M | 1 |
| Zhumabekov, Z | 1 |
| Kuandykov, Y | 1 |
| Tazhiyeva, A | 1 |
| Abdrakhmanova, Z | 1 |
| Omarova, B | 1 |
| Tasbulatov, N | 1 |
| Ratcliffe, SJ | 1 |
| Sherlock, LG | 1 |
| Oncel, MY | 7 |
| Eras, Z | 2 |
| Uras, N | 9 |
| Canpolat, FE | 5 |
| Erdeve, O | 17 |
| Oguz, SS | 8 |
| Jansen, EJS | 1 |
| Salas, R | 1 |
| Lavín, P | 1 |
| Rincón, Y | 1 |
| Miranda, J | 1 |
| López, M | 1 |
| Ngo, S | 1 |
| Profit, J | 1 |
| Gould, JB | 1 |
| Lee, HC | 2 |
| Bixler, GM | 1 |
| Powers, GC | 1 |
| Clark, RH | 2 |
| Walker, MW | 1 |
| Tolia, VN | 1 |
| Raaijmakers, A | 1 |
| Zhang, ZY | 1 |
| Levtchenko, E | 2 |
| Simons, SH | 2 |
| Cauwenberghs, N | 1 |
| Heuvel, LPVD | 1 |
| Jacobs, L | 1 |
| Staessen, JA | 1 |
| Allegaert, K | 5 |
| Zung, A | 1 |
| Bier Palmon, R | 1 |
| Golan, A | 1 |
| Troitzky, M | 1 |
| Eventov-Friedman, S | 1 |
| Keidar, R | 3 |
| Kats, N | 1 |
| Almashanu, S | 1 |
| Flidel-Rimon, O | 1 |
| Boghossian, NS | 1 |
| Do, BT | 1 |
| Bell, EF | 1 |
| Dagle, JM | 1 |
| Brumbaugh, JE | 1 |
| Stoll, BJ | 1 |
| Vohr, BR | 1 |
| Das, A | 1 |
| Shankaran, S | 1 |
| Sanchez, PJ | 1 |
| Wyckoff, MH | 1 |
| Bethany Ball, M | 1 |
| Huang, X | 1 |
| Wang, F | 1 |
| Wang, K | 1 |
| Benitz, WE | 2 |
| Bhombal, S | 1 |
| Watson, H | 1 |
| Babayigit, A | 1 |
| Ozaydın, S | 1 |
| Cetinkaya, M | 1 |
| Sander, S | 1 |
| Cartledge, PT | 1 |
| Umuhoza, C | 1 |
| Harrison, C | 1 |
| Al-Lawama, M | 1 |
| Alammori, I | 1 |
| Abdelghani, T | 1 |
| Badran, E | 1 |
| Garcia, J | 1 |
| Garg, A | 1 |
| Song, Y | 1 |
| Fotios, A | 1 |
| Andersen, C | 1 |
| Garg, S | 1 |
| Cianchi, I | 1 |
| Corsini, I | 2 |
| Vangi, V | 5 |
| Pratesi, S | 3 |
| Hu, Y | 1 |
| Jin, H | 1 |
| Jiang, Y | 1 |
| Du, J | 1 |
| Lewis, TR | 1 |
| Shelton, EL | 2 |
| Van Driest, SL | 1 |
| Kannankeril, PJ | 1 |
| Wyllie, JP | 2 |
| Florez, ID | 2 |
| Tamayo, ME | 2 |
| Mbuagbaw, L | 2 |
| Vanniyasingam, T | 1 |
| Veroniki, AA | 2 |
| Zea, AM | 1 |
| Sadeghirad, B | 1 |
| Thabane, L | 2 |
| El-Farrash, RA | 1 |
| El Shimy, MS | 1 |
| El-Sakka, AS | 1 |
| Ahmed, MG | 1 |
| Abdel-Moez, DG | 1 |
| Hochwald, O | 1 |
| Mainzer, G | 1 |
| Borenstein-Levin, L | 1 |
| Jubran, H | 1 |
| Dinur, G | 1 |
| Zucker, M | 1 |
| Mor, M | 1 |
| Khoury, A | 1 |
| Kugelman, A | 1 |
| Stremming, JE | 1 |
| Brown, LD | 1 |
| Singh, GK | 1 |
| Nichols, CG | 1 |
| Khuwuthyakorn, V | 2 |
| Jatuwattana, C | 1 |
| Silvilairat, S | 2 |
| Tantiprapha, W | 1 |
| Cuzzolin, L | 4 |
| Bardanzellu, F | 1 |
| Fanos, V | 7 |
| Romagnoli, V | 1 |
| Pedini, A | 1 |
| Santoni, M | 1 |
| Scutti, G | 1 |
| Colaneri, M | 1 |
| Pozzi, M | 1 |
| Cogo, PE | 1 |
| Carnielli, VP | 1 |
| Farooqui, MA | 1 |
| Elsayed, YN | 1 |
| Jeyaraman, MM | 1 |
| Dingwall, O | 1 |
| Tagin, M | 1 |
| Zarychanski, R | 1 |
| Rabbani, R | 1 |
| Abou-Setta, AM | 1 |
| Ter Heine, R | 1 |
| Spaans, E | 1 |
| Burger, DM | 1 |
| de Klerk, JCA | 1 |
| Dijk, P | 1 |
| van Kaam, AHLC | 1 |
| de Tollenaer, SM | 1 |
| Cools, F | 1 |
| van Laere, D | 1 |
| Johansson, AB | 1 |
| Adang, E | 1 |
| de Vries, W | 1 |
| van Heijst, AFJ | 1 |
| Halil, H | 1 |
| Buyuktiryaki, M | 2 |
| Atay, FY | 1 |
| Ding, Y | 1 |
| Wang, X | 3 |
| Wu, Y | 1 |
| Li, H | 1 |
| Xu, J | 1 |
| Collins, RT | 1 |
| Lyle, RE | 1 |
| Rettiganti, M | 1 |
| Gossett, JM | 1 |
| Robbins, JM | 2 |
| Casey, PH | 1 |
| Olsson, KW | 3 |
| Larsson, A | 1 |
| Jonzon, A | 2 |
| Sindelar, R | 3 |
| Clyman, RI | 9 |
| Liebowitz, M | 2 |
| Kaempf, J | 2 |
| Bulbul, A | 2 |
| Lindqvist, J | 2 |
| Farooqi, A | 2 |
| Katheria, A | 2 |
| Sauberan, J | 2 |
| Singh, J | 2 |
| Nelson, K | 2 |
| Wickremasinghe, A | 3 |
| Dong, L | 2 |
| Hassinger, DC | 3 |
| Aucott, SW | 2 |
| Hayashi, M | 2 |
| Heuchan, AM | 2 |
| Carey, WA | 4 |
| Derrick, M | 3 |
| Sankar, M | 2 |
| Leone, T | 2 |
| Perez, J | 2 |
| Serize, A | 2 |
| Ferretti, E | 1 |
| Tremblay, E | 1 |
| Thibault, MP | 1 |
| Fallah, S | 1 |
| Grynspan, D | 1 |
| Burghardt, KM | 1 |
| Bettolli, M | 1 |
| Babakissa, C | 1 |
| Levy, E | 1 |
| Beaulieu, JF | 1 |
| Ferguson, JM | 1 |
| Yadav, A | 2 |
| Stritzke, A | 1 |
| Soraisham, AS | 2 |
| Wolf, IS | 1 |
| Kimball, A | 1 |
| Karabulut, B | 1 |
| Paytoncu, S | 1 |
| Guler Kazanci, E | 1 |
| Cristea, S | 1 |
| Falcao, AC | 1 |
| Falcao, F | 1 |
| Silva, R | 1 |
| Smits, A | 1 |
| Cresi, F | 1 |
| Lago, P | 6 |
| Paolillo, P | 1 |
| Trevisanuto, D | 3 |
| Capasso, L | 1 |
| Maffei, G | 1 |
| Boni, L | 1 |
| Aydin, T | 1 |
| Hort, S | 1 |
| Kubinski, A | 1 |
| Bode, C | 1 |
| Klippstein, T | 1 |
| Endesfelder, S | 1 |
| Bührer, C | 3 |
| Koehne, P | 6 |
| Tantiprabha, W | 1 |
| Poon, WB | 1 |
| Tagamolila, V | 1 |
| Lu, J | 1 |
| Li, Q | 1 |
| Zhu, L | 1 |
| Chen, C | 1 |
| Li, Z | 1 |
| Jhaveri, N | 1 |
| Attridge, JT | 1 |
| Sanocka, U | 1 |
| Polin, R | 1 |
| Gillam-Krakauer, M | 3 |
| Mammel, M | 1 |
| Couser, R | 1 |
| Mulrooney, N | 1 |
| Yanowitz, TD | 2 |
| Jegatheesan, P | 2 |
| Walsh, M | 2 |
| Fujii, A | 2 |
| Porta, N | 1 |
| Swanson, JR | 1 |
| Dilmen, U | 13 |
| Walia, R | 6 |
| Tripathi, A | 1 |
| Black, GB | 1 |
| Park, YM | 1 |
| Jerrell, JM | 1 |
| Guzoglu, N | 1 |
| Sari, FN | 1 |
| Altug, N | 8 |
| Yapakçı, E | 1 |
| Ecevit, A | 1 |
| Törer, B | 1 |
| Ince, DA | 1 |
| Gökdemir, M | 1 |
| Gülcan, H | 1 |
| Tarcan, A | 1 |
| Bravo, MC | 2 |
| Cabañas, F | 2 |
| Riera, J | 1 |
| Pérez-Fernández, E | 1 |
| Quero, J | 1 |
| Pérez-Rodríguez, J | 2 |
| Pellicer, A | 2 |
| Härkin, P | 1 |
| Dang, D | 1 |
| Wang, D | 1 |
| Zhang, C | 1 |
| Zhou, W | 1 |
| Zhou, Q | 1 |
| Wu, H | 1 |
| Salvadori, S | 3 |
| Opocher, F | 1 |
| Ricato, S | 1 |
| Chiandetti, L | 2 |
| Frigo, AC | 2 |
| Cochran, CM | 1 |
| Lau, J | 1 |
| Tran, VT | 1 |
| Fabio, A | 1 |
| Youn, YA | 1 |
| Moon, CJ | 1 |
| Kim, SY | 3 |
| Lee, JY | 3 |
| Sung, IK | 2 |
| Cordeiro, M | 1 |
| Deiros, L | 1 |
| Yadav, S | 1 |
| Agarwal, S | 1 |
| Maria, A | 1 |
| Dudeja, A | 1 |
| Dubey, NK | 1 |
| Anand, P | 1 |
| Yadav, DK | 1 |
| Coceani, F | 2 |
| Chan, NM | 1 |
| Law, CW | 1 |
| Kwan, KF | 1 |
| DeMauro, SB | 1 |
| Pacifici, GM | 2 |
| Durand, DJ | 1 |
| Danielsen, B | 1 |
| Dueñas, GV | 1 |
| Powers, RJ | 1 |
| Ding, YJ | 1 |
| Han, B | 1 |
| Yang, B | 1 |
| Zhu, M | 1 |
| ElHassan, NO | 1 |
| Bird, TM | 1 |
| King, AJ | 1 |
| Ambadwar, PB | 1 |
| Jaquiss, RD | 1 |
| Kaiser, JR | 1 |
| Malikiwi, A | 1 |
| Roufaeil, C | 1 |
| Gudmundsdottir, A | 2 |
| Johansson, S | 2 |
| Källen, K | 2 |
| Bonamy, AK | 2 |
| Demir, N | 2 |
| Ece, İ | 2 |
| Peker, E | 2 |
| Kaba, S | 1 |
| Ustyol, L | 1 |
| Balahoroğlu, R | 2 |
| Tuncer, O | 2 |
| Inayat, M | 1 |
| Bany-Mohammed, F | 1 |
| Valencia, A | 1 |
| Tay, C | 1 |
| Jacinto, J | 1 |
| Aranda, JV | 9 |
| Beharry, KD | 4 |
| Meyer, S | 1 |
| Madeleneau, D | 1 |
| Aubelle, MS | 1 |
| Pierron, C | 1 |
| Lopez, E | 1 |
| Jarreau, PH | 1 |
| Roofthooft, DW | 1 |
| van Beynum, IM | 1 |
| de Klerk, JC | 1 |
| Reiss, IK | 1 |
| Tibboel, D | 1 |
| Takmil, F | 1 |
| Cheriki, S | 1 |
| Şahin, İO | 1 |
| Dinlen Fettah, N | 1 |
| Kara, M | 1 |
| Demirelli, Y | 1 |
| Tekgündüz, KŞ | 2 |
| Yolcu, C | 1 |
| Olgun, H | 2 |
| Ceviz, N | 2 |
| Lu, D | 1 |
| Liu, Y | 1 |
| Tong, X | 1 |
| Terrin, G | 1 |
| Conte, F | 1 |
| Scipione, A | 1 |
| Simons, S | 1 |
| Sinha, R | 1 |
| Dogan, M | 1 |
| Nadir, E | 1 |
| Alan, S | 1 |
| Manguso, F | 1 |
| De Curtis, M | 1 |
| Gulack, BC | 1 |
| Laughon, MM | 1 |
| Sankar, MN | 1 |
| Hornik, CP | 1 |
| Smith, PB | 3 |
| Lee, JA | 2 |
| Kim, MJ | 1 |
| Oh, S | 2 |
| Choi, BM | 1 |
| Bourgoin, L | 1 |
| Cipierre, C | 1 |
| Hauet, Q | 1 |
| Basset, H | 1 |
| Gournay, V | 2 |
| Lainwala, S | 2 |
| Hussain, N | 1 |
| Zhou, K | 1 |
| Tang, J | 1 |
| Hua, Y | 1 |
| Shi, X | 1 |
| Wang, Y | 1 |
| Qiao, L | 1 |
| Mu, D | 1 |
| Akar, S | 1 |
| Karadag, N | 1 |
| Gokmen Yildirim, T | 1 |
| Toptan, HH | 1 |
| Dincer, E | 1 |
| Tuten, A | 1 |
| Yavuz, T | 1 |
| Topcuoglu, S | 1 |
| Karatepe, HO | 1 |
| Ozalkaya, E | 1 |
| Karatekin, G | 1 |
| Ovali, F | 1 |
| Hansmann, G | 2 |
| Slaughter, JL | 1 |
| Reagan, PB | 1 |
| Bapat, RV | 1 |
| Newman, TB | 1 |
| Klebanoff, MA | 1 |
| Mohanty, PK | 1 |
| Nagesh, NK | 1 |
| Sivanandan, S | 2 |
| Agarwal, R | 1 |
| Romagnoli, C | 5 |
| Salvatori, E | 1 |
| Valerio, E | 1 |
| Valente, MR | 1 |
| Baraldi, E | 1 |
| Vettukattil, JJ | 1 |
| Tan, ZH | 1 |
| Rostas, SE | 1 |
| McPherson, CC | 1 |
| Haw, MP | 1 |
| Kartal, İ | 1 |
| Caner, İ | 1 |
| Karacan, M | 1 |
| Taştekin, A | 1 |
| Becit, N | 1 |
| Terek, D | 1 |
| Altun Koroglu, O | 1 |
| Ulger, Z | 1 |
| Yalaz, M | 1 |
| Kultursay, N | 1 |
| Akar, M | 1 |
| Yildirim, TG | 1 |
| Sandal, G | 1 |
| Bozdag, S | 1 |
| Joppi, R | 1 |
| Gerardi, C | 1 |
| Bertele', V | 1 |
| Garattini, S | 1 |
| Aune, D | 1 |
| Tofé Valera, I | 1 |
| Jaraba Caballero, MP | 1 |
| Ruiz González, MD | 1 |
| Rodríguez Benítez, MV | 1 |
| Parraga Quiles, MJ | 1 |
| Hagadorn, JI | 1 |
| Brownell, EA | 1 |
| Trzaski, JM | 1 |
| Johnson, KR | 1 |
| Campbell, BT | 1 |
| Herbst, KW | 1 |
| Bancalari, E | 3 |
| Shin, SH | 2 |
| Kim, HS | 2 |
| Jung, YH | 2 |
| Kim, EK | 2 |
| Choi, JH | 1 |
| Prescott, S | 1 |
| Keim-Malpass, J | 1 |
| Lin, YJ | 1 |
| Chen, CM | 1 |
| Rehan, VK | 1 |
| Florens, A | 1 |
| Wu, SY | 1 |
| Tsai, ML | 1 |
| Kuo, YT | 1 |
| Huang, FK | 1 |
| Yeh, TF | 1 |
| Yoo, H | 1 |
| Sohn, JA | 1 |
| Choi, CW | 1 |
| Kim, BI | 1 |
| El-Mashad, AE | 1 |
| El-Mahdy, H | 1 |
| El Amrousy, D | 1 |
| Elgendy, M | 1 |
| Jain, D | 1 |
| Letshwiti, JB | 1 |
| Semberova, J | 1 |
| Pichova, K | 1 |
| Dempsey, EM | 1 |
| Franklin, OM | 1 |
| Miletin, J | 1 |
| Kalani, M | 1 |
| Shariat, M | 1 |
| Khalesi, N | 1 |
| Farahani, Z | 1 |
| Ahmadi, S | 1 |
| Yen, TA | 1 |
| Wang, CC | 1 |
| Zanardo, V | 2 |
| Vedovato, S | 2 |
| Chiozza, L | 1 |
| Faggian, D | 2 |
| Favaro, F | 2 |
| Pereira-da-Silva, L | 1 |
| Pita, A | 1 |
| Virella, D | 1 |
| Serelha, M | 1 |
| Bertini, G | 5 |
| Elia, S | 1 |
| Rubaltelli, FF | 4 |
| Pai, VB | 1 |
| Sakadjian, A | 1 |
| Puthoff, TD | 1 |
| Sheffield, MJ | 1 |
| Schmutz, N | 1 |
| Lambert, DK | 1 |
| Henry, E | 1 |
| Christensen, RD | 1 |
| Rheinlaender, C | 2 |
| Helfenstein, D | 2 |
| Walch, E | 3 |
| Berns, M | 1 |
| Obladen, M | 3 |
| Cherif, A | 2 |
| Khrouf, N | 2 |
| Jabnoun, S | 2 |
| Mokrani, C | 1 |
| Amara, MB | 1 |
| Guellouze, N | 1 |
| Kacem, S | 1 |
| Antonucci, R | 2 |
| Arceri, A | 1 |
| Dessì, A | 2 |
| Cox, B | 1 |
| Wozniak, P | 1 |
| Sosenko, I | 1 |
| Carlo, WA | 1 |
| Ward, RM | 1 |
| Shalwitz, R | 1 |
| Baggs, G | 1 |
| Seth, A | 1 |
| Darko, L | 1 |
| Ferdinus, C | 1 |
| Labenne, M | 1 |
| Golombek, SG | 1 |
| Sola, A | 1 |
| Baquero, H | 1 |
| Borbonet, D | 1 |
| Fajardo, C | 1 |
| Goldsmit, G | 1 |
| Lemus, L | 1 |
| Miura, E | 1 |
| Pérez, JM | 1 |
| Rogido, M | 1 |
| Zambosco, G | 1 |
| Momma, K | 1 |
| Toyoshima, K | 1 |
| Ito, K | 1 |
| Sugiyama, K | 1 |
| Imamura, S | 1 |
| Sun, F | 1 |
| Nakanishi, T | 1 |
| Sangtawesin, C | 2 |
| Sangtawesin, V | 2 |
| Lertsutthiwong, W | 1 |
| Kanjanapattanakul, W | 2 |
| Khorana, M | 2 |
| Ayudhaya, JK | 1 |
| Gokmen, T | 4 |
| Vida, VL | 1 |
| Salvatori, S | 1 |
| Boccuzzo, G | 1 |
| Padalino, MA | 1 |
| Milanesi, O | 1 |
| Speggiorin, S | 1 |
| Stellin, G | 1 |
| Yokoi, T | 2 |
| Hiraoka, M | 1 |
| Miyamoto, M | 1 |
| Kobayashi, Y | 1 |
| Nishina, S | 1 |
| Azuma, N | 1 |
| De Carolis, MP | 4 |
| Costa, S | 1 |
| Marra, R | 1 |
| De Luca, D | 1 |
| Richards, J | 1 |
| Johnson, A | 1 |
| Fox, G | 1 |
| Campbell, M | 1 |
| Gebrekristos, B | 1 |
| Brock, RS | 1 |
| Kuniyoshi, K | 1 |
| Abad-Santos, P | 2 |
| Abad-Santos, M | 2 |
| Modanlou, HD | 2 |
| Bratlid, D | 1 |
| Farstad, T | 1 |
| Tefft, RG | 1 |
| Ghodstehrani, M | 1 |
| Pishva, N | 1 |
| Schimmel, MS | 2 |
| Bromiker, R | 2 |
| Kaplan, M | 4 |
| Nir, A | 2 |
| Vieux, R | 2 |
| Desandes, R | 2 |
| Boubred, F | 4 |
| Semama, D | 1 |
| Guillemin, F | 1 |
| Buchweiller, MC | 1 |
| Fresson, J | 1 |
| Hascoet, JM | 2 |
| Mercanti, I | 2 |
| Simeoni, U | 3 |
| Valencia, GB | 1 |
| Linder, N | 1 |
| Bello, R | 1 |
| Hernandez, A | 1 |
| Rosen, C | 1 |
| Birk, E | 1 |
| Sirota, L | 1 |
| Pushkov, Y | 1 |
| Klinger, G | 1 |
| Katakam, LI | 1 |
| Cotten, CM | 2 |
| Goldberg, RN | 2 |
| Dang, CN | 1 |
| Pees, C | 2 |
| Czernik, C | 1 |
| Diot, C | 1 |
| Kibleur, Y | 3 |
| Desfrere, L | 4 |
| Loeliger, M | 1 |
| Shields, A | 1 |
| McCurnin, D | 4 |
| Yoder, B | 3 |
| Inder, TE | 1 |
| Rees, SM | 1 |
| Hovhannisyan, S | 1 |
| Médard, Y | 1 |
| Jacqz-Aigrain, E | 1 |
| Decobert, F | 1 |
| Barre, J | 1 |
| Alberti, C | 1 |
| Aujard, Y | 1 |
| Danan, C | 1 |
| Baud, O | 1 |
| Jones, LJ | 1 |
| Craven, PD | 1 |
| Attia, J | 1 |
| Thakkinstian, A | 1 |
| Wright, I | 1 |
| Longini, M | 1 |
| Perrone, S | 1 |
| Vezzosi, P | 1 |
| Proietti, F | 1 |
| Marzocchi, B | 1 |
| Buonocore, G | 1 |
| Brunoldi, E | 1 |
| Amin, SB | 1 |
| Miravalle, N | 1 |
| Sekar, KC | 2 |
| Bagnoli, F | 2 |
| Rossetti, A | 2 |
| Casucci, M | 2 |
| Mori, A | 2 |
| Waleh, N | 2 |
| McCurnin, DC | 1 |
| Yoder, BA | 2 |
| Shaul, PW | 2 |
| Li, Y | 1 |
| Zelenina, M | 1 |
| Plat-Willson, G | 1 |
| Marcoux, MO | 1 |
| Aperia, A | 1 |
| Casper, C | 1 |
| Rao, R | 1 |
| Bryowsky, K | 1 |
| Bunton, D | 1 |
| McPherson, C | 1 |
| Mathur, A | 1 |
| Brissaud, O | 1 |
| Guichoux, J | 1 |
| Ethington, PN | 1 |
| Katakam, L | 1 |
| George, I | 1 |
| Mekahli, D | 1 |
| Rayyan, M | 2 |
| Sasi, A | 1 |
| Deorari, A | 1 |
| Kushnir, A | 1 |
| Pinheiro, JM | 1 |
| Jellimann, JM | 1 |
| Rouabah, M | 1 |
| Haddad, F | 1 |
| Desandes, E | 1 |
| Semama, DS | 1 |
| Thibaut, C | 2 |
| Hazard, A | 1 |
| Huon, C | 1 |
| Ciarmoli, E | 1 |
| Barzilay, B | 1 |
| Youngster, I | 1 |
| Batash, D | 2 |
| Baram, S | 2 |
| Goldman, M | 1 |
| Berkovitch, M | 2 |
| Heyman, E | 2 |
| Demirel, G | 2 |
| Celik, IH | 2 |
| Barbier, A | 1 |
| Bordarier, C | 1 |
| Moriette, G | 2 |
| Bersani, I | 1 |
| De Rosa, G | 1 |
| Cota, F | 1 |
| Roberts, C | 1 |
| Berrington, J | 1 |
| Embleton, N | 1 |
| Dhami, S | 1 |
| Lori, I | 1 |
| Favelli, F | 1 |
| Ciuti, R | 1 |
| Bandinelli, A | 1 |
| Martano, C | 2 |
| Murru, P | 2 |
| Messner, H | 1 |
| Amitai, Y | 1 |
| Pusceddu, M | 1 |
| Marcialis, MA | 1 |
| Sosenko, IR | 1 |
| Fajardo, MF | 1 |
| Claure, N | 1 |
| Adrouche-Amrani, L | 1 |
| Green, RS | 1 |
| Gluck, KM | 1 |
| Lin, J | 1 |
| Meißner, U | 1 |
| Chakrabarty, R | 1 |
| Topf, HG | 1 |
| Rascher, W | 1 |
| Schroth, M | 1 |
| Johnston, PG | 1 |
| Fuller, MP | 1 |
| Sutherland, MR | 1 |
| Seidner, S | 2 |
| Gubhaju, L | 1 |
| Black, MJ | 1 |
| Neumann, R | 1 |
| Schulzke, SM | 1 |
| Bhatt, M | 1 |
| Petrova, A | 1 |
| Mehta, R | 1 |
| Amendolia, B | 1 |
| Lynn, M | 1 |
| Bhat, V | 1 |
| Ritz, SB | 1 |
| Aghai, ZH | 1 |
| Sarici, SU | 1 |
| Dabak, O | 1 |
| Erdinc, K | 1 |
| Okutan, V | 1 |
| Lenk, MK | 1 |
| El-Khuffash, AF | 1 |
| Mertens, L | 1 |
| Mezu-Ndubuisi, OJ | 1 |
| Agarwal, G | 1 |
| Raghavan, A | 1 |
| Pham, JT | 1 |
| Ohler, KH | 1 |
| Grandvuillemin, I | 1 |
| Buffat, C | 2 |
| Fayol, L | 1 |
| Millet, V | 2 |
| Ekmen, S | 1 |
| Lin, XZ | 1 |
| Chen, HQ | 1 |
| Zheng, Z | 1 |
| Li, YD | 1 |
| Lai, JD | 1 |
| Huang, LH | 1 |
| Kumarshingri, PS | 1 |
| van der Lugt, NM | 1 |
| Lopriore, E | 1 |
| Bökenkamp, R | 1 |
| Smits-Wintjens, VE | 1 |
| Steggerda, SJ | 1 |
| Weber, SC | 1 |
| Hüning, B | 1 |
| Stein, A | 1 |
| Horn, PA | 1 |
| Metze, BC | 1 |
| Dame, C | 1 |
| Felderhoff-Müser, U | 1 |
| Fontanelli, G | 1 |
| Sajan Saini, S | 1 |
| Mahajan, V | 1 |
| Youn, Y | 1 |
| Lee, JH | 1 |
| Heo, MJ | 1 |
| Lee, OS | 1 |
| Lim, SC | 1 |
| Messina, G | 1 |
| Tomasini, B | 1 |
| Kanmaz, G | 1 |
| Greijdanus, B | 1 |
| Lee, CH | 1 |
| Chen, HN | 1 |
| Tsao, LY | 1 |
| Hsiao, CC | 1 |
| Lee, ML | 1 |
| Zhang, CC | 1 |
| Cheng, GQ | 1 |
| Bali, V | 1 |
| Harabor, A | 1 |
| Kamaluddeen, M | 1 |
| Ozyurt, BM | 1 |
| Saridas, B | 1 |
| Schmidt, B | 1 |
| Wright, LL | 1 |
| Davis, P | 1 |
| Solimano, A | 1 |
| Roberts, RS | 1 |
| Bray, M | 4 |
| Stucchi, I | 2 |
| Fumagalli, M | 4 |
| Supapannachart, S | 1 |
| Limrungsikul, A | 1 |
| Khowsathit, P | 1 |
| Hansen, TW | 1 |
| Shah, S | 3 |
| Pugni, L | 1 |
| Agosti, M | 1 |
| Morag, I | 1 |
| Su, PH | 1 |
| Chen, JY | 1 |
| Su, CM | 1 |
| Huang, TC | 1 |
| Lee, HS | 1 |
| Swartz, EN | 1 |
| Chotigeat, U | 1 |
| Jirapapa, K | 1 |
| Layangkool, T | 1 |
| Tatli, MM | 1 |
| Kumral, A | 1 |
| Duman, N | 1 |
| Demir, K | 1 |
| Gurcu, O | 1 |
| Ozkan, H | 1 |
| Keady, S | 1 |
| Grosso, A | 1 |
| Chemtob, S | 3 |
| Thomas, RL | 1 |
| Parker, GC | 1 |
| Distefano, G | 1 |
| Benini, D | 1 |
| Verlato, G | 1 |
| Zohar, S | 1 |
| Morville, P | 1 |
| Brunhes, A | 1 |
| Chevret, S | 1 |
| Pons, G | 1 |
| Rey, E | 1 |
| Pezzati, M | 2 |
| Guerrini, P | 1 |
| Plebani, M | 1 |
| Gimeno Navarro, A | 2 |
| Cano Sánchez, A | 1 |
| Fernández Gilino, C | 2 |
| Carrasco Moreno, JI | 1 |
| Izquierdo Macián, I | 2 |
| Gutiérrez Laso, A | 2 |
| Morcillo Sopena, F | 2 |
| Jaillard, S | 1 |
| Larrue, B | 1 |
| Rakza, T | 1 |
| Magnenant, E | 1 |
| Warembourg, H | 1 |
| Storme, L | 1 |
| Raksasinborisut, C | 1 |
| Sathirakul, K | 1 |
| Horpaopan, S | 1 |
| Bellini, C | 1 |
| Campone, F | 1 |
| Serra, G | 1 |
| Thomas, R | 1 |
| Anderson, BJ | 1 |
| Vanhaesebrouck, S | 1 |
| Zonnenberg, I | 1 |
| Vandervoort, P | 1 |
| Bruneel, E | 1 |
| Van Hoestenberghe, MR | 1 |
| Theyskens, C | 1 |
| Tiker, F | 1 |
| Yildirim, SV | 1 |
| Giniger, RP | 1 |
| Aly, H | 1 |
| Lotfy, W | 1 |
| Badrawi, N | 1 |
| Ghawas, M | 1 |
| Abdel-Meguid, IE | 1 |
| Hammad, TA | 1 |
| Su, BH | 1 |
| Chiu, HY | 1 |
| Hsieh, HY | 1 |
| Chen, HH | 1 |
| Tsai, YC | 1 |
| Fakhraee, SH | 1 |
| Badiee, Z | 1 |
| Mojtahedzadeh, S | 1 |
| Kazemian, M | 1 |
| Kelishadi, R | 1 |
| Modesto Alapont, V | 1 |
| Hasan, J | 1 |
| Gharraee, Z | 1 |
| Stavitsky, Y | 1 |
| Chang, LY | 2 |
| Hirt, D | 1 |
| Langhendries, JP | 2 |
| Marguglio, A | 1 |
| Eisinger, MJ | 1 |
| Schepens, P | 1 |
| Urien, S | 1 |
| Corff, KE | 1 |
| Ikegami, M | 1 |
| Petershack, J | 1 |
| Giavedoni, L | 1 |
| Albertine, KH | 1 |
| Dahl, MJ | 1 |
| Wang, ZM | 1 |
| Jacobson, S | 1 |
| Furst, DE | 1 |
| Grosfeld, JL | 1 |
| Kamman, K | 1 |
| Gross, K | 1 |
| Cikrit, D | 1 |
| Ross, D | 1 |
| Wolfe, M | 1 |
| Katz, S | 1 |
| Weber, TR | 1 |
| Olley, PM | 1 |
| Patel, J | 2 |
| Marks, KA | 1 |
| Roberts, I | 2 |
| Azzopardi, D | 2 |
| Edwards, AD | 2 |
| Varvarigou, A | 2 |
| Bardin, CL | 1 |
| Beharry, K | 2 |
| Papageorgiou, A | 2 |
| Bansal, R | 1 |
| Bardin, C | 1 |
| Modanlou, H | 1 |
| Follens, I | 1 |
| Hartmann, S | 1 |
| Creten, WL | 1 |
| Van Acker, KJ | 1 |
| Lattanzio, M | 1 |
| Tosetto, C | 1 |
| Edwards, D | 1 |
| Gupta, P | 1 |
| Colnaghi, MR | 1 |
| Compagnoni, G | 1 |
| Biagiotti, R | 1 |
| Cianciulli, D | 1 |
| Hamilton, P | 1 |
| Polimeni, V | 2 |
| Piersigilli, F | 2 |
| Papacci, P | 2 |
| Delogu, AB | 2 |
| Tortorolo, G | 2 |
| Luciano, R | 1 |
| SoRelle, R | 1 |
| Smets, K | 1 |
| Lecoutere, D | 1 |
| Van de Broek, H | 1 |
| Weyler, J | 1 |
| Degroote, K | 1 |
| Cotton, RB | 1 |
| Reali, MF | 1 |
| Fabris, C | 1 |
| Sunnegårdh, J | 1 |
| Dal Cerè, M | 1 |
| Casalaz, D | 1 |
| Adamska, E | 1 |
| Drukker, A | 1 |
| Guignard, JP | 1 |
| Aggarwal, R | 1 |
| Bajpai, A | 1 |
| Deorari, AK | 1 |
| Paul, VK | 1 |
| Hariprasad, P | 1 |
| Sundarrajan, V | 1 |
| Srimathy, G | 1 |
| Suthagar, B | 1 |
| Ramadevi, BS | 1 |
| Hey, E | 1 |
| Savagner, C | 1 |
| Thiriez, G | 1 |
| Kuster, A | 1 |
| Bettiol, T | 1 |
| Pitassi, I | 1 |
| Vianello, A | 1 |
| Saia, OS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-center, Randomized Non-inferiority Trial of Early Treatment Versus Expectative Management of Patent Ductus Arteriosus in Preterm Infants (BeNeDuctus Trial - Belgium Netherlands Ductus Trial)[NCT02884219] | 273 participants (Actual) | Interventional | 2016-12-23 | Completed | |||
| Drug Utilization Patterns in Neonatal Units in the UK: a Retrospective Pharmaco-epidemiological Study[NCT03773289] | 642,729 participants (Actual) | Observational | 2018-04-20 | Completed | |||
| Long Term Follow-up of the TREOCAPA (Prophylactic TREatment Of the duCtus Arteriosus in Preterm Infants by Acetaminophen) Study (TREOCAPA-LT)[NCT06064825] | 500 participants (Anticipated) | Observational | 2023-11-30 | Not yet recruiting | |||
| Efficacy and Safety of No Treatment Compared With Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants: a Randomized, Double-blind, Placebo-controlled, Non-inferiority Clinical Trial[NCT02128191] | Phase 2 | 142 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Efficacy and Safety of Paracetamol in Comparison to Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants: A Randomized, Open Label, Comparator-controlled, Prospective Study[NCT02422966] | Phase 2 | 110 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Comparison of The Effect of Continuous and Standard Intermittent Boluses Paracetamol Infusion on Patent Ductus Arteriosus[NCT04469413] | 138 participants (Actual) | Observational | 2019-01-01 | Completed | |||
| Impact of Early Targeted Ibuprofene Treatment of Patent Ductus Arteriosus (PDA) on Long Term Neurodevelopmental Outcome in Very Premature Infants (TRIOCAPI)[NCT01630278] | Phase 3 | 363 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Relative Effectiveness and Safety of Pharmacotherapeutic Agents for Patent Ductus Arteriosus (PDA) in Preterm Infants: A National Comparative Effectiveness Research (CER) Project[NCT04347720] | 1,350 participants (Anticipated) | Observational [Patient Registry] | 2020-01-01 | Recruiting | |||
| Oral Paracetamol Versus Oral Ibuprofen Treatment[NCT01536158] | Phase 4 | 80 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Prematurity as Predictor of Children's Cardiovascular-renal Health (PREMATCH)[NCT02147457] | 180 participants (Actual) | Observational | 2014-10-31 | Completed | |||
| Generic Database: A Survey of Morbidity and Mortality in Very Low Birth Weight Infants[NCT00063063] | 80,000 participants (Anticipated) | Observational | 1987-01-31 | Recruiting | |||
| Follow-up Visit of High Risk Infants[NCT00009633] | 68,000 participants (Anticipated) | Observational | 1993-01-31 | Recruiting | |||
| Comparison Between the Effect of Oral Paracetamol Versus Oral Ibuprofen in the Treatment of Patent Ductus Arteriosus in Preterm and Low Birth Weight Infants[NCT03265782] | Phase 4 | 30 participants (Actual) | Interventional | 2015-06-30 | Active, not recruiting | ||
| Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus in Preterm infants-a Multicenter Trial[NCT01958320] | Phase 2 | 202 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Should Very Low Birth Weight Infants Receive Enteral Nutrition During Indomethacin or Ibuprofen Treatment of a Patent Ductus Arteriosus? A Multi-Center Randomized Controlled Trial[NCT00728117] | 177 participants (Actual) | Interventional | 2008-07-31 | Completed | |||
| Liberal Versus Restrictive Platelet Transfusion for Treatment of Hemodynamically Significant Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates- A Randomized Open Label, Controlled Trial[NCT03022253] | Phase 3 | 44 participants (Anticipated) | Interventional | 2016-03-31 | Completed | ||
| Extremely Low Gestational Age Infants' Paracetamol Study: a Randomized Trial[NCT03641209] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2018-09-03 | Active, not recruiting | ||
| Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus of Preterm Infants - Randomised, Placebo-controlled Multicentre Trial[NCT03648437] | Phase 1 | 60 participants (Anticipated) | Interventional | 2018-09-03 | Recruiting | ||
| Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus in Premature Infants: A Pilot Study[NCT03103022] | Phase 1 | 20 participants (Actual) | Interventional | 2017-06-12 | Completed | ||
| Paracetamol Versus Ibuprofen in Premature Infants With Hemodynamically Significant Patent Ductus Arteriosus: a Randomized Clinical Trial[NCT04037514] | Phase 3 | 300 participants (Anticipated) | Interventional | 2017-07-07 | Recruiting | ||
| Comparison of the Efficacy of IV Acetaminophen Versus IV Indomethacin in Treatment of Hemodynamically Significant PDA in VLBW Infants[NCT03537144] | Phase 3 | 37 participants (Actual) | Interventional | 2016-06-30 | Terminated (stopped due to Difficulty enrolling patients) | ||
| TIME TO RE-EVALUATE THE KINDER GENTLER APPROACH TO PATENT DUCTUS ARTERIOSUS (PDA) IN THE PRETERM NEONATE[NCT02819414] | Phase 2 | 80 participants (Anticipated) | Interventional | 2016-06-30 | Active, not recruiting | ||
| Treatment of a PDA With Acetaminophen in Preterm Neonates: Exploring Various Indications[NCT03289390] | 11 participants (Actual) | Observational | 2017-08-01 | Completed | |||
| Randomized Pilot Study Comparing Oral Ibuprofen With Intravenous Ibuprofen in Very Low Birth Weight Infants With Patent Ductus Arteriosus[NCT00642330] | Phase 4 | 62 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| The Best Treatment Strategy: Surgical Versus Pharmacological, to Close the Ductus Arteriosus Persistent in Preterm Infants. A Randomized Controlled Trial[NCT02602054] | Phase 2 | 40 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| Oral Ibuprofen Prophylaxis for Patent Ductus Arterioses in Very Extremely Low Birth Weight Infants[NCT01400737] | 200 participants (Anticipated) | Interventional | 2011-07-31 | Recruiting | |||
| Ibuprofen and Renal Function in Premature Infants[NCT00217191] | Phase 4 | 120 participants | Interventional | 2004-09-30 | Completed | ||
| High-dose Ibuprofen for Patent Ductus Arteriosus in Extremely Preterm Infants: a Randomized Controlled Study[NCT01243996] | Phase 2/Phase 3 | 70 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Timing of PDA Closure and Respiratory Outcome in Premature Infants[NCT00802685] | 105 participants (Actual) | Interventional | 2007-11-30 | Terminated (stopped due to Lack of availability of IV ibuprofen as of 8/10 due to a manufacturer's recall) | |||
| Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants[NCT01755728] | Phase 3 | 19 participants (Actual) | Interventional | 2013-01-01 | Completed | ||
| Paracetamol Versus Ibuprofen for Patent Ductus Arteriosus Closure in Preterm Infants. A Prospective, Randomized, Controlled, Double Blind, Multicenter Clinical Trial.[NCT02056223] | Phase 2/Phase 3 | 120 participants (Anticipated) | Interventional | 2017-01-09 | Suspended (stopped due to We enrolled only 53 patients) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
duration of gavage feeding assistance (NCT01958320)
Timeframe: up to 20 weeks of age
| Intervention | days (Median) |
|---|---|
| Early Treatment | 76 |
| Conservative Treatment | 80 |
incidence of bacteremia (NCT01958320)
Timeframe: through hospital discharge (approximately 6 months unless death occurs first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 31 |
| Conservative Treatment | 21 |
incidence of bronchopulmonary dysplasia or death (NCT01958320)
Timeframe: determined between 36-37 weeks corrected age
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 60 |
| Conservative Treatment | 56 |
incidence of death (NCT01958320)
Timeframe: through hospital discharge (approximately 6 months unless death occurs first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 20 |
| Conservative Treatment | 10 |
incidence of necrotizing enterocolitis or spontaneous perforation (NCT01958320)
Timeframe: through hospital discharge (approximately 6 months unless death occurs first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 17 |
| Conservative Treatment | 19 |
incidence of pulmonary hemorrhage (NCT01958320)
Timeframe: through hospital discharge (approximately 6 months unless death occurs first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 2 |
| Conservative Treatment | 2 |
number of infants receiving ≥ 14 days of diuretic treatment (NCT01958320)
Timeframe: through hospital discharge (approximately 6 months unless death occurs first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 36 |
| Conservative Treatment | 45 |
number of infants who received dopamine for ≥3 days (NCT01958320)
Timeframe: through hospital discharge (approximately 6 months unless death occurs first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 14 |
| Conservative Treatment | 25 |
Number of infants who undergo in hospital PDA ligations or who have an open ductus at the time of discharge (that need future outpatient cardiology follow-up visits) (NCT01958320)
Timeframe: through hospital discharge (approximately 6 months unless death occurs first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 33 |
| Conservative Treatment | 38 |
the average daily weight gain (NCT01958320)
Timeframe: up to 20 weeks of age
| Intervention | gm/kg/day (Mean) |
|---|---|
| Early Treatment | 22.5 |
| Conservative Treatment | 22.8 |
"the incidence of persistent moderate-to-large PDA shunt 10 days after enrollment The echocardiographic studies included two dimensional imaging, M-mode, color flow mapping and Doppler interrogation as previously described. A moderate-to-large PDA was defined by a ductus internal diameter ≥ 1.5mm (or PDA:left pulmonary artery diameter ratio ≥0.5) and one or more of the following echocardiographic criteria: a) left atrium-to-aortic root (LA/Ao) ratio ≥1.6, b) ductus flow velocity ≤2.5m/sec or mean pressure gradient across the ductus ≤8mm, c) left pulmonary artery diastolic flow velocity > 0.2 m/sec, and/or d) reversed diastolic flow in the descending aorta. Ductus that failed to meet these criteria were considered to be constricted (small or closed) and not eligible for enrollment or treatment." (NCT01958320)
Timeframe: 10 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 43 |
| Conservative Treatment | 78 |
"Infants were eligible for rescue PDA drug treatment if they met one or more of the following prespecified Rescue criteria: 1) Inotrope-dependent hypotension for at least 3 days. 2) Oliguria that persisted for at least 2 days with no obvious cause, other than the moderate PDA, to explain the condition. 3) Requirement for gavage feedings beyond 35 weeks corrected age due to increased work of breathing. 4) Respiratory support needed after the following postnatal ages that surpassed specific minimal ventilation and FiO2 requirements: >15 days (if still required intubation and FiO2 >0.30), >20 days (if still required intubation and FiO2 ≤0.30; or still required Nasal CPAP or Nasal ventilation and FiO2 >0.30), >30 days (if still required Nasal CPAP or Nasal ventilation and FiO2 0.25-0.30), and >45 days (if still required Nasal CPAP or Nasal ventilation and FiO2 <0.25)." (NCT01958320)
Timeframe: through hospital discharge (approximately 6 months unless death occurs first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Treatment | 32 |
| Conservative Treatment | 61 |
(NCT00802685)
Timeframe: 28 days of life
| Intervention | days (Median) |
|---|---|
| Early Ibuprofen | 21 |
| Late Ibuprofen Expectant Group | 19 |
(NCT00802685)
Timeframe: at 36 weeks postmenstrual age
| Intervention | participants (Number) |
|---|---|
| Early Ibuprofen | 17 |
| Late Ibuprofen Expectant Group | 16 |
89 reviews available for ibuprofen and Ductus Arteriosus, Patent
| Article | Year |
|---|---|
Comparative safety and efficacy of paracetamol versus non-steroidal anti-inflammatory agents in neonates with patent ductus arteriosus: A systematic review and meta-analysis of randomized controlled trials.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen | 2022 |
Efficacy and Costs of Three Pharmacotherapies for Patent Ductus Arteriosus Closure in Premature Infants.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, Premature; Infa | 2022 |
Dual Therapy vs. Monotherapy for the Patent Ductus Arteriosus: A Systematic Review.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; Infant, Newbor | 2022 |
Efficacy and safety of high versus standard dose ibuprofen for patent ductus arteriosus treatment in preterm infants: A systematic review and meta-analysis.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low B | 2022 |
Dual medication therapy (acetaminophen and ibuprofen) for the management of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2022 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; | 2023 |
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.
Topics: Acetaminophen; Drug Therapy, Combination; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin | 2022 |
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.
Topics: Acetaminophen; Drug Therapy, Combination; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin | 2022 |
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.
Topics: Acetaminophen; Drug Therapy, Combination; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin | 2022 |
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.
Topics: Acetaminophen; Drug Therapy, Combination; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin | 2022 |
Association of patent ductus arteriosus with fetal factors and endotypes of prematurity.
Topics: Ductus Arteriosus, Patent; Female; Fetal Growth Retardation; Humans; Ibuprofen; Indomethacin; Infant | 2023 |
Combination pharmacotherapy for patent ductus arteriosus: Rationale and evidence.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; Infant, Newbor | 2023 |
Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews.
Topics: Acetaminophen; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin | 2023 |
Acetaminophen for the patent ductus arteriosus: has safety been adequately demonstrated?
Topics: Acetaminophen; Cytochrome P-450 CYP2E1; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; | 2023 |
Expectant management of patent ductus arteriosus for preterm infants: A meta-analysis of randomized controlled trials.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; Infant, Newbor | 2023 |
An Overview of Systematic Reviews of Randomized-Controlled Trials for Preventing Necrotizing Enterocolitis in Preterm Infants.
Topics: Administration, Oral; Adrenal Cortex Hormones; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing | 2020 |
To Feed or Not to Feed: A Critical Overview of Enteral Feeding Management and Gastrointestinal Complications in Preterm Neonates with a Patent Ductus Arteriosus.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Ductus Arteriosus | 2019 |
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.
Topics: Acetaminophen; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin | 2020 |
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Drug-Related Side Effects and Adverse Reactions; Duc | 2020 |
Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Cerebral Intraventricular Hemorrhage; Chron | 2020 |
Early closure mechanisms of the ductus arteriosus in immature infants.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant; Infant, Newbo | 2021 |
Feeding Strategies in Preterm Very Low Birth-Weight Infants: State-of-the-Science Review.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newborn; Infant, Premature; Infant, Very Low B | 2021 |
Acetaminophen Therapy for Persistent Patent Ductus Arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Extremely Prematu | 2021 |
Paracetamol versus ibuprofen for the treatment of patent ductus arteriosus in preterm neonates: a meta-analysis of randomized controlled trials.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infant, Newborn; Infant, Premat | 2018 |
The use of non-steroidal anti-inflammatory drugs for patent ductus arteriosus closure in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; | 2017 |
Prediction of Therapeutic Response to Cyclooxygenase Inhibitors in Preterm Infants with Patent Ductus Arteriosus.
Topics: Biomarkers, Pharmacological; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography; | 2018 |
Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.
Topics: Acetaminophen; Animals; Disease Models, Animal; Ductus Arteriosus, Patent; Genetic Predisposition to | 2018 |
Prophylactic and early targeted treatment of patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, Premature | 2018 |
Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.
Topics: Acetaminophen; Administration, Intravenous; Administration, Oral; Bayes Theorem; Cerebral Hemorrhage | 2018 |
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.
Topics: Acetaminophen; Administration, Oral; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Inf | 2018 |
Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus; Ductus Arteriosu | 2018 |
The dark side of ibuprofen in the treatment of patent ductus arteriosus: could paracetamol be the solution?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Rela | 2018 |
Pre-symptomatic targeted treatment of patent ductus arteriosus in preterm newborns: A systematic review and meta-analysis.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography; Humans; Ibuprofen; Indometha | 2019 |
Pharmacotherapy for patent ductus arteriosus closure.
Topics: Acetaminophen; Administration, Oral; Antipyretics; Cyclooxygenase Inhibitors; Ductus Arteriosus, Pat | 2019 |
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Enterocolit | 2019 |
The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia.
Topics: Animals; Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Disease Models, Animal; Ductus Arter | 2013 |
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Humans; Ibuprofen; | 2013 |
Therapeutic manipulation of the ductus arteriosus: current options and future prospects.
Topics: Ductus Arteriosus, Patent; Female; Forecasting; Hemodynamics; Humans; Ibuprofen; Indomethacin; Infan | 2014 |
Clinical pharmacology of ibuprofen and indomethacin in preterm infants with patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Dinoprostone; Drug Administration Schedule; Ductus Arteriosus, Patent; Fe | 2014 |
Safety of therapeutics used in management of patent ductus arteriosus in preterm infants.
Topics: Acetaminophen; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indo | 2015 |
Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enterocolitis, Necrotizi | 2015 |
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low-birth-weight infants.
Topics: Acetaminophen; Administration, Oral; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Inf | 2015 |
Paracetamol for the treatment of patent ductus arteriosus in preterm neonates: a systematic review and meta-analysis.
Topics: Acetaminophen; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newb | 2016 |
Paracetamol for the treatment of patent ductus arteriosus in preterm neonates: a systematic review and meta-analysis.
Topics: Acetaminophen; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newb | 2016 |
Paracetamol for the treatment of patent ductus arteriosus in preterm neonates: a systematic review and meta-analysis.
Topics: Acetaminophen; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newb | 2016 |
Paracetamol for the treatment of patent ductus arteriosus in preterm neonates: a systematic review and meta-analysis.
Topics: Acetaminophen; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newb | 2016 |
[Transcatheter occlusion of patent ductus arteriosus in a preterm infant and review of literatures].
Topics: Birth Weight; Body Weight; China; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibupro | 2016 |
Recent Advances in the Treatment of Preterm Newborn Infants with Patent Ductus Arteriosus.
Topics: Acetaminophen; Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents, Non-Ster | 2016 |
Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Decision Making; Drug Administra | 2016 |
Principles of Clinical Management of Patent Ductus Arteriosus in Extremely Preterm Neonates.
Topics: Acetaminophen; Anterior Cerebral Artery; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echoc | 2016 |
Pharmacotherapy for Patent Ductus Arteriosus: Current Options and Outstanding Questions.
Topics: Acetaminophen; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; | 2016 |
Surgical Intervention in Preterm Neonates with Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Combined Modality Therapy; Cyclooxygenase Inhibitors; Ductus Arteriosus, | 2016 |
Letting post-marketing bridge the evidence gap: the case of orphan drugs.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineo | 2016 |
Patent Ductus Arteriosus and Short- and Long-Term Respiratory Outcomes.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Hemodynamics; Humans; Ibuprofen; Indomethacin | 2016 |
Patent Ductus Arteriosus in the Preterm Infant: Diagnostic and Treatment Options.
Topics: Biomarkers; Cardiac Catheterization; Conservative Treatment; Cyclooxygenase Inhibitors; Ductus Arter | 2017 |
Ibuprofen lysine for the prevention and treatment of patent ductus arteriosus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Fetus; Humans; Ib | 2008 |
Therapeutic closure of the ductus arteriosus: benefits and limitations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Evidence-Based Medicine; Gestati | 2009 |
Nonsteroidal anti-inflammatory drugs (NSAIDs) in the newborn - which ones?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Hemorrhage; Humans; Ibuprofen; I | 2009 |
Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiac Surgical Procedures; Confidence Intervals; Ductus A | 2010 |
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low B | 2010 |
Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants.
Topics: Cardiovascular Agents; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprof | 2011 |
Patent ductus arteriosus in the preterm infant: to treat or not to treat?
Topics: Blood Circulation; Case Management; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ib | 2010 |
Protective strategies to prevent patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Ligation; Tim | 2010 |
Efficacy and tolerability of enteral formulations of ibuprofen in the treatment of patent ductus arteriosus in preterm infants.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Ductus Arte | 2010 |
Patent ductus arteriosus in preterm infants.
Topics: Biomarkers; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography; Humans; Ibuprofe | 2011 |
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enzyme Inhibitors; Humans; Ibuprofen; Infant, | 2011 |
Effect of ibuprofen on bilirubin-albumin binding during the treatment of patent ductus arteriosus in preterm infant.
Topics: Albumins; Anti-Inflammatory Agents, Non-Steroidal; Bilirubin; Ductus Arteriosus, Patent; Humans; Ibu | 2011 |
New therapeutic strategies for the treatment of patent ductus arteriosus in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newbo | 2011 |
Patent ductus arteriosus: wait and see?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; | 2011 |
Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Extre | 2011 |
Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Evidence-Based Medicine; Humans; Ibuprofen; In | 2012 |
Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indom | 2012 |
Managing the patent ductus arteriosus in the premature neonate: a new look at what we thought we knew.
Topics: Acetaminophen; Biomarkers; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Echocardiogr | 2012 |
Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.
Topics: Acetazolamide; Bumetanide; Drug Therapy, Combination; Ductus Arteriosus, Patent; Extracorporeal Memb | 2012 |
[Progresses in treatment of patent ductus arteriosus in premature infants].
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Wei | 2012 |
The use of ibuprofen in neonates in the treatment of patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Ductus Arteriosus, Patent; Humans; Ibu | 2003 |
Ibuprofen for the treatment of a patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enzyme Inhibitors; Humans; Ibuprofen; Infant, | 2003 |
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enzyme Inhibitors; Humans; Ibuprofen; Infant, | 2003 |
Is indomethacin or ibuprofen better for medical closure of the patent ductus arteriosus?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Agents; Ductus Arteriosus, Patent; Humans; I | 2003 |
Ibuprofen in the management of neonatal Patent Ductus Arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newbo | 2005 |
The pharmacologic closure of the patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indometh | 2005 |
A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Creatinine; Ductus Arteriosus, Patent; Humans; Ibuprofen; I | 2005 |
[The pharmacological manipulation of Botallo's duct in the duct-dependent congenital cardiopathies and in the preterm infants with respiratory distress. A review and personal findings].
Topics: Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Agents; Cerebral Angiography; C | 2005 |
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enzyme Inhibitors; Humans; Ibuprofen; Indometh | 2005 |
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enzyme Inhibitors; Humans; Ibuprofen; Infant, | 2006 |
Systematic review: intravenous Ibuprofen in preterm newborns.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indom | 2006 |
Renal effects of ibuprofen for the treatment of patent ductus arteriosus in premature infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newborn; Renal Insu | 2007 |
[Ibuprofen versus indomethacin in the preterm persistent patent ductus arteriosus therapy: review and meta-analysis].
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echoca | 2007 |
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low B | 2008 |
Treatment of patent ductus arteriosus: indomethacin or ibuprofen?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Human | 2008 |
Role of prostaglandins, prostacyclin, and thromboxanes in the control of prenatal patency and postnatal closure of the ductus arteriosus.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Animals; Arachidonic Acids; Ductus Arteriosus; Ductus Arteriosus, P | 1980 |
NSAID-induced nephrotoxicity from the fetus to the child.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Ductus Arteriosus, Patent; Female; | 2001 |
[Ibuprofen--a new application for pharmacological closure of patent ductus arteriosus in preterm infants. Preliminary report].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Clinical Trials as Topic; Ductu | 2000 |
Comparative tolerability of pharmacological treatments for patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2001 |
Patent ductus arteriosus in preterm neonates.
Topics: Cyclooxygenase Inhibitors; Diagnosis, Differential; Ductus Arteriosus, Patent; Echocardiography; Hum | 2001 |
88 trials available for ibuprofen and Ductus Arteriosus, Patent
| Article | Year |
|---|---|
Multi-centre, randomised non-inferiority trial of early treatment versus expectant management of patent ductus arteriosus in preterm infants (the BeNeDuctus trial): statistical analysis plan.
Topics: Child, Preschool; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Low Birth Weight; In | 2021 |
Low dose paracetamol for management of patent ductus arteriosus in very preterm infants: a randomised non-inferiority trial.
Topics: Acetaminophen; Double-Blind Method; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newborn; I | 2023 |
Combined (dual) drug therapy for the treatment of patent ductus arteriosus: last approach prior to ligation.
Topics: Acetaminophen; Drug Therapy, Combination; Ductus Arteriosus, Patent; Echocardiography; Female; Human | 2023 |
Combined (dual) drug therapy for the treatment of patent ductus arteriosus: last approach prior to ligation.
Topics: Acetaminophen; Drug Therapy, Combination; Ductus Arteriosus, Patent; Echocardiography; Female; Human | 2023 |
Combined (dual) drug therapy for the treatment of patent ductus arteriosus: last approach prior to ligation.
Topics: Acetaminophen; Drug Therapy, Combination; Ductus Arteriosus, Patent; Echocardiography; Female; Human | 2023 |
Combined (dual) drug therapy for the treatment of patent ductus arteriosus: last approach prior to ligation.
Topics: Acetaminophen; Drug Therapy, Combination; Ductus Arteriosus, Patent; Echocardiography; Female; Human | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
The dilemma of feeding during the treatment of patent ductus arteriosus with oral ibuprofen in preterm infants ≤30 weeks of gestation-a randomized controlled trial.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infant, Newborn; In | 2023 |
Platelets and ductus arteriosus closure in neonates.
Topics: Animals; Cyclooxygenase Inhibitors; Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Ibuprofen; | 2023 |
Cardiopulmonary Ultrasound-Guided Treatment of Premature Infants with Respiratory Failure and Patent Ductus Arteriosus: A Randomized, Controlled Trial.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low B | 2023 |
iPAPP: study protocol for a multicentre randomised controlled trial comparing safety and efficacy of intravenous paracetamol and indomethacin for the treatment of patent ductus arteriosus in preterm infants.
Topics: Acetaminophen; Administration, Intravenous; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethac | 2023 |
Oral Paracetamol vs Oral Ibuprofen in Patent Ductus Arteriosus: A Randomized, Controlled, Noninferiority Trial.
Topics: Acetaminophen; Administration, Oral; Double-Blind Method; Ductus Arteriosus, Patent; Female; Humans; | 2020 |
A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants.
Topics: Acetaminophen; Administration, Oral; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Inf | 2021 |
Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Gestational Age; Humans; Ibuprofen; Infant; Infant, Newbor | 2021 |
Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Dinopr | 2020 |
A Pilot Randomized Controlled Trial of Early Targeted Patent Ductus Arteriosus Treatment Using a Risk Based Severity Score (The PDA RCT).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infan | 2021 |
Effect of Early Targeted Treatment of Ductus Arteriosus with Ibuprofen on Survival Without Cerebral Palsy at 2 Years in Infants with Extreme Prematurity: A Randomized Clinical Trial.
Topics: Cerebral Palsy; Child, Preschool; Cyclooxygenase Inhibitors; Double-Blind Method; Ductus Arteriosus, | 2021 |
Effect of Early Targeted Treatment of Ductus Arteriosus with Ibuprofen on Survival Without Cerebral Palsy at 2 Years in Infants with Extreme Prematurity: A Randomized Clinical Trial.
Topics: Cerebral Palsy; Child, Preschool; Cyclooxygenase Inhibitors; Double-Blind Method; Ductus Arteriosus, | 2021 |
Effect of Early Targeted Treatment of Ductus Arteriosus with Ibuprofen on Survival Without Cerebral Palsy at 2 Years in Infants with Extreme Prematurity: A Randomized Clinical Trial.
Topics: Cerebral Palsy; Child, Preschool; Cyclooxygenase Inhibitors; Double-Blind Method; Ductus Arteriosus, | 2021 |
Effect of Early Targeted Treatment of Ductus Arteriosus with Ibuprofen on Survival Without Cerebral Palsy at 2 Years in Infants with Extreme Prematurity: A Randomized Clinical Trial.
Topics: Cerebral Palsy; Child, Preschool; Cyclooxygenase Inhibitors; Double-Blind Method; Ductus Arteriosus, | 2021 |
Study protocol: baby-OSCAR trial: Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Low Birth | 2021 |
Patent ductus arteriosus shunt elimination results in a reduction in adverse outcomes: a post hoc analysis of the PDA RCT cohort.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Weight; Infant, Newbor | 2021 |
Early PARacetamol (EPAR) Trial: A Randomized Controlled Trial of Early Paracetamol to Promote Closure of the Ductus Arteriosus in Preterm Infants.
Topics: Acetaminophen; Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newborn; Inf | 2021 |
Relative effectiveness and safety of pharmacotherapeutic agents for patent ductus arteriosus (PDA) in preterm infants: a protocol for a multicentre comparative effectiveness study (CANRxPDA).
Topics: Canada; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant; Infant, Low Birth Weight | 2021 |
Baby-OSCAR: Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies-a statistical analysis plan for short-term outcomes.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Extremely | 2021 |
Neurodevelopmental Outcomes of Preterm Infants Treated with Oral Paracetamol Versus Ibuprofen for Patent Ductus Arteriosus.
Topics: Acetaminophen; Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; F | 2017 |
Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indom | 2017 |
Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indom | 2017 |
Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indom | 2017 |
Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indom | 2017 |
Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Case-Control Studies; Double-Blind Method; Ductus Arteriosus, P | 2019 |
Adding Paracetamol to Ibuprofen for the Treatment of Patent Ductus Arteriosus in Preterm Infants: A Double-Blind, Randomized, Placebo-Controlled Pilot Study.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Metho | 2018 |
Oral indomethacin versus oral ibuprofen for treatment of patent ductus arteriosus: a randomised controlled study in very low-birthweight infants.
Topics: Administration, Oral; Cardiovascular Agents; Ductus Arteriosus, Patent; Echocardiography; Female; Hu | 2018 |
Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus trial).
Topics: Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enterocolitis, Necrotiz | 2018 |
PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age.
Topics: Acetaminophen; Conservative Treatment; Continuous Positive Airway Pressure; Cyclooxygenase Inhibitor | 2019 |
PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age.
Topics: Acetaminophen; Conservative Treatment; Continuous Positive Airway Pressure; Cyclooxygenase Inhibitor | 2019 |
PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age.
Topics: Acetaminophen; Conservative Treatment; Continuous Positive Airway Pressure; Cyclooxygenase Inhibitor | 2019 |
PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age.
Topics: Acetaminophen; Conservative Treatment; Continuous Positive Airway Pressure; Cyclooxygenase Inhibitor | 2019 |
Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320).
Topics: Acetaminophen; Administration, Intravenous; Administration, Oral; Conservative Treatment; Ductus Art | 2019 |
Enteral feeding during indomethacin and ibuprofen treatment of a patent ductus arteriosus.
Topics: Combined Modality Therapy; Ductus Arteriosus, Patent; Enteral Nutrition; Female; Humans; Ibuprofen; | 2013 |
The relationship between trough drug concentrations and ductal closure in preterm infants treated with three-dose-oral ibuprofen.
Topics: Administration, Oral; Birth Weight; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Fem | 2013 |
Randomised controlled clinical trial of standard versus echocardiographically guided ibuprofen treatment for patent ductus arteriosus in preterm infants: a pilot study.
Topics: Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Echocardiography; Female; Gestational A | 2014 |
Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Ductus Arteriosus, Patent; Female; Gestational Age; Heart; Huma | 2013 |
Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Ductus Arteriosus, Patent; Female; Gestational Age; Heart; Huma | 2013 |
Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Ductus Arteriosus, Patent; Female; Gestational Age; Heart; Huma | 2013 |
Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Ductus Arteriosus, Patent; Female; Gestational Age; Heart; Huma | 2013 |
Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Ductus Arteriosus, Patent; Female; Gestational Age; Heart; Huma | 2013 |
Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Ductus Arteriosus, Patent; Female; Gestational Age; Heart; Huma | 2013 |
Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Ductus Arteriosus, Patent; Female; Gestational Age; Heart; Huma | 2013 |
Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Ductus Arteriosus, Patent; Female; Gestational Age; Heart; Huma | 2013 |
Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Ductus Arteriosus, Patent; Female; Gestational Age; Heart; Huma | 2013 |
Continuous infusion of ibuprofen for treatment of patent ductus arteriosus in very low birth weight infants.
Topics: Double-Blind Method; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; Female | 2014 |
Superior mesenteric artery blood flow velocities following medical treatment of a patent ductus arteriosus.
Topics: Blood Flow Velocity; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enteral Nutrition; Female | 2014 |
Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; I | 2014 |
Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; I | 2014 |
Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; I | 2014 |
Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; I | 2014 |
Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; I | 2014 |
Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; I | 2014 |
Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; I | 2014 |
Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; I | 2014 |
Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; I | 2014 |
Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofe | 2014 |
NT-proBNP plays an important role in the effect of ibuprofen on preterm infants with patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infant, Premature; Male; Natriuretic Peptide, | 2014 |
The Effect of Oral High-dose Ibuprofen on Patent Ductus Arteriosus Closure in Preterm Infants.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography, Dopple | 2015 |
May we use ibuprofen as doses against courses in the treatment of patent ductus arteriosus in premature infants?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newbo | 2016 |
Efficacy and safety of intravenous paracetamol in comparison to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: study protocol for a randomized control trial.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Clinical Protocols | 2016 |
Does ibuprofen treatment in patent ductus arteriosus alter oxygen free radicals in premature infants?
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Biomarkers; Dose-Respon | 2017 |
Randomized Trial to Compare Renal Function and Ductal Response between Indomethacin and Ibuprofen Treatment in Extremely Low Birth Weight Infants.
Topics: Creatinine; Cyclooxygenase Inhibitors; Double-Blind Method; Ductus Arteriosus; Ductus Arteriosus, Pa | 2017 |
Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; Cyclooxygenase Inhibitors; Ductus Art | 2017 |
Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; Cyclooxygenase Inhibitors; Ductus Art | 2017 |
Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; Cyclooxygenase Inhibitors; Ductus Art | 2017 |
Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; Cyclooxygenase Inhibitors; Ductus Art | 2017 |
Efficacy and safety of rectal ibuprofen for patent ductus arteriosus closure in very low birth weight preterm infants.
Topics: Administration, Oral; Administration, Rectal; Biomarkers; Case-Control Studies; Cyclooxygenase Inhib | 2017 |
A Comparison of Early Ibuprofen and Indomethacin Administration to Prevent Intraventricular Hemorrhage Among Preterm Infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Ductus Arte | 2016 |
Pharmacological closure of patent ductus arteriosus: effects on pulse pressure and on endothelin-1 and vasopressin excretion.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arginine Vasopressin; Blood Pressure; Ductus Arteriosus, Pa | 2008 |
Ibuprofen lysine administration to neonates with a patent ductus arteriosus: effect on platelet plug formation assessed by in vivo and in vitro measurements.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Ductus Arteriosus, Patent; Female; Gestationa | 2009 |
Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Dru | 2008 |
A randomized, double-blind, placebo-controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants.
Topics: Double-Blind Method; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infant, Extremely Low Bir | 2009 |
Prophylaxis of symptomatic patent ductus arteriosus with oral ibuprofen in very low birth weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Ductus Arteriosus, Patent; Female; Hum | 2008 |
Oral ibuprofen and ductus arteriosus closure in full-term neonates: a prospective case-control study.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Ductus Arteriosu | 2010 |
Ibuprofen in very preterm infants impairs renal function for the first month of life.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Creatinine; Cyclooxygenase Inhibitors; Ductus Arteriosus, P | 2010 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Echocardiography as a guide for patent ductus arteriosus ibuprofen treatment and efficacy prediction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Drug Administration Schedule; Ductus Arteri | 2012 |
Pharmacokinetics of oral ibuprofen for patent ductus arteriosus closure in preterm infants.
Topics: Administration, Oral; Birth Weight; Cyclooxygenase Inhibitors; Drug Administration Schedule; Ductus | 2012 |
Unbound bilirubin does not increase during ibuprofen treatment of patent ductus arteriosus in preterm infants.
Topics: Albumins; Bilirubin; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Ductus Arteriosus, | 2012 |
High-dose ibuprofen for patent ductus arteriosus in extremely preterm infants: a randomized controlled study.
Topics: Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infant, Extr | 2012 |
Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants.
Topics: Administration, Oral; Birth Weight; Chronic Disease; Cyclooxygenase Inhibitors; Ductus Arteriosus, P | 2012 |
Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial.
Topics: Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Ductus Arteriosus, | 2012 |
Improved closure of patent ductus arteriosus with high doses of ibuprofen.
Topics: Body Weight; Cardiac Surgical Procedures; Cyclooxygenase Inhibitors; Dose-Response Relationship, Dru | 2012 |
[Therapeutic effect of early administration of oral ibuprofen in very low birth weight infants with patent ductus arteriosus].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Hu | 2012 |
Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns.
Topics: Birth Weight; Blood Urea Nitrogen; Creatinine; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; | 2013 |
Serum ibuprofen levels of extremely preterm infants treated prophylactically with oral ibuprofen to prevent patent ductus arteriosus.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Hu | 2013 |
Impact of oral versus intravenous ibuprofen on neurodevelopmental outcome: a randomized controlled parallel study.
Topics: Administration, Intravenous; Administration, Oral; Blindness; Case-Control Studies; Cerebral Palsy; | 2013 |
Ibuprofen prophylaxis in preterm neonates.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Hypertension, Pulmonary; Hypoxia; Ibup | 2002 |
Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Hu | 2002 |
Comparison of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Femal | 2003 |
A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofe | 2003 |
Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method.
Topics: Bayes Theorem; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Double-Blind Met | 2005 |
Prophylactic ibuprofen for the prevention of intraventricular hemorrhage among preterm infants: a multicenter, randomized study.
Topics: Cerebral Hemorrhage; Cerebral Ventricles; Cerebrovascular Circulation; Double-Blind Method; Ductus A | 2005 |
[Ibuprofen versus indomethacin in the treatment of patent ductus arteriosus in preterm infants].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indom | 2005 |
Oral ibuprofen prophylaxis for symptomatic patent ductus arteriosus of prematurity.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography; Female; Humans; Ibuprofen; I | 2006 |
Impact of ibuprofen administration on renal drug clearance in the first weeks of life.
Topics: Age Factors; Amikacin; Anti-Bacterial Agents; Aspirin; Betamethasone; Birth Weight; Cyclooxygenase I | 2006 |
Oral Ibuprofen and ductus arteriosus in premature infants: a randomized pilot study.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echocardio | 2007 |
Comparison of ibuprofen and indometacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial.
Topics: Analysis of Variance; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Ductus Arteriosus | 2008 |
Comparison of oral ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants.
Topics: Administration, Oral; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Humans; Ibuprofen; Indo | 2007 |
Ibuprofen versus continuous indomethacin in premature neonates with patent ductus arteriosus: is the difference in the mode of administration?
Topics: Blood Flow Velocity; Cerebral Arteries; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Glomer | 2008 |
Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants.
Topics: Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Ductus Arteriosu | 1996 |
Treatment of patent ductus arteriosus with ibuprofen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Ductus Arteriosus, Patent; Ec | 1997 |
Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus.
Topics: Blood Flow Velocity; Brain; Cerebrovascular Circulation; Cyclooxygenase Inhibitors; Dose-Response Re | 1997 |
Ibuprofen vs indomethacin for treatment of PDA in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Drug Administration Sched | 1998 |
Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newbo | 1999 |
Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus.
Topics: Brain; Double-Blind Method; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newb | 2000 |
Prophylactic ibuprofen therapy of patent ductus arteriosus in preterm infants.
Topics: Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, Prematu | 2000 |
Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Echocardiography, Doppl | 2000 |
A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2000 |
Prophylaxis of patent ductus arteriosus with ibuprofen in preterm infants.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Apgar Score; Birth Weight; Cyclooxygenase Inhi | 2000 |
Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants.
Topics: Analgesics, Non-Narcotic; Ductus Arteriosus, Patent; Electrocardiography; Humans; Hypertension, Pulm | 2002 |
Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial.
Topics: Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Ductus Art | 2002 |
234 other studies available for ibuprofen and Ductus Arteriosus, Patent
| Article | Year |
|---|---|
Hypotension and significant patent ductus arteriosus in infants born extremely preterm during the postnatal transitional period: normal adaptation?
Topics: Adaptation, Physiological; Ductus Arteriosus, Patent; Humans; Hypotension; Ibuprofen; Infant; Infant | 2022 |
Prophylactic intravenous paracetamol use in extremely premature infants for patent ductus arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Extremely Premature; Infant, Ne | 2020 |
Retrospective comparison of death or neurodevelopmental outcomes in extremely low birth weight preterm infants following different management options of haemodynamically significant patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Extremely Low Birth Weight; Infant, Ne | 2021 |
Assessing patent ductus arteriosus in preterm infants from standard neonatal intensive care monitoring.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Extremely Premature; Infant, Newborn; | 2022 |
Does Early Neonatal Thrombocytopenia Affect Ductal Therapeutic Response to Acetaminophen in Preterm Neonates?
Topics: Acetaminophen; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newb | 2022 |
Oral versus intravenous paracetamol for patent ductus arteriosus closure in preterm infants.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newborn; Infant, Premature; Pro | 2022 |
What Should be the First-line Treatment for the Closure of Hemodynamically Significant Patent Ductus Arteriosus in Premature Infants?
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Low Birth Weight; Infan | 2022 |
Survey highlighting the lack of consensus on diagnosis and treatment of patent ductus arteriosus in prematurity.
Topics: Consensus; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, Prem | 2022 |
A perspective on the potential side effects of paracetamol use in the treatment of PDA.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newbo | 2022 |
The Effect of Ibuprofen Exposure and Patient Characteristics on the Closure of the Patent Ductus Arteriosus in Preterm Infants.
Topics: Birth Weight; Ductus Arteriosus, Patent; Gestational Age; Humans; Ibuprofen; Infant, Newborn; Infant | 2022 |
Acute liver failure secondary to therapeutic paracetamol dosing in an extremely preterm neonate.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Extremely Premature; In | 2022 |
Paracetamol Treatment for Patent Ductus Arteriosus, an Apparent Association with Acute Hemolysis in Three Preterm Infants: Case Series.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Hemolysis; Humans; Ibuprofen; Infant, Newborn; Infant, Pre | 2022 |
Single-dose prophylactic ibuprofen therapy for patent ductus arteriosus in preterm infants.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Low Birth Weight; | 2022 |
Patent ductus arteriosus in a late preterm neonate: think congenital hypopituitarism.
Topics: Ductus Arteriosus, Patent; Female; Humans; Hydrocortisone; Hypopituitarism; Hypothyroidism; Ibuprofe | 2022 |
Management of patent ductus arteriosus in very preterm infants in England and Wales: a retrospective cohort study.
Topics: Ductus Arteriosus, Patent; Female; Fetal Growth Retardation; Humans; Ibuprofen; Indomethacin; Infant | 2022 |
Percutaneous Closure of Ductus Arteriosus in Preterm Babies: The Initial Brazilian Experience.
Topics: Brazil; Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Newborn; In | 2022 |
Oral Ibuprofen Is More Effective than Intravenous Ibuprofen for Closure of a Patent Ductus Arteriosus: Can Pharmacokinetic Modeling Help Us to Understand Why?
Topics: Administration, Oral; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth | 2023 |
Oral Ibuprofen Is More Effective than Intravenous Ibuprofen for Closure of a Patent Ductus Arteriosus: Can Pharmacokinetic Modeling Help Us to Understand Why?
Topics: Administration, Oral; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth | 2023 |
Oral Ibuprofen Is More Effective than Intravenous Ibuprofen for Closure of a Patent Ductus Arteriosus: Can Pharmacokinetic Modeling Help Us to Understand Why?
Topics: Administration, Oral; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth | 2023 |
Oral Ibuprofen Is More Effective than Intravenous Ibuprofen for Closure of a Patent Ductus Arteriosus: Can Pharmacokinetic Modeling Help Us to Understand Why?
Topics: Administration, Oral; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth | 2023 |
Predictors of a non-response to prophylactic indomethacin for patent ductus arteriosus in preterm infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indomethacin; Infan | 2023 |
Association between gastrointestinal perforation and patent ductus arteriosus in extremely-low-birth-weight infants: a retrospective study of our decade-long experience.
Topics: Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Humans; Ibuprofen; Indomethacin; Infant, Extr | 2023 |
The association between patterns of early respiratory disease and diastolic dysfunction in preterm infants.
Topics: Ductus Arteriosus, Patent; Gestational Age; Humans; Ibuprofen; Infant; Infant, Low Birth Weight; Inf | 2023 |
Evaluation of Health-Related Values and Preferences of Adults Who Were Preterm Infants and Parents of Preterm Infants Concerning Use of Prophylactic Cyclooxygenase Inhibitor Drugs.
Topics: Acetaminophen; Adult; Cerebral Hemorrhage; Child; Cross-Sectional Studies; Cyclooxygenase Inhibitors | 2023 |
Cost-Effectiveness Analysis of Ibuprofen Versus Indomethacin or Paracetamol for the Treatment of Patent Ductus Arteriosus in Preterm Neonates.
Topics: Acetaminophen; Cost-Effectiveness Analysis; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Hu | 2023 |
Prophylactic low-dose paracetamol for ductal closure and neurodevelopmental outcome in very preterm infants.
Topics: Acetaminophen; Child; Child, Preschool; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant | 2023 |
EBNEO commentary: Expectant management or early ibuprofen for patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newbo | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newbo | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus. Reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newbo | 2023 |
Early neurodevelopmental outcomes of extreme preterm infants exposed to paracetamol: a retrospective cohort study.
Topics: Acetaminophen; Birth Weight; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infant; Infant, N | 2023 |
Increasing the dose of ibuprofen with postnatal age to close a hemodynamically significant patent ductus arteriosus in very preterm infants.
Topics: Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infant, Newborn; Infant, Premature; Infant, Pr | 2023 |
Is Expectant Management Noninferior to Early Ibuprofen for Patent Ductus Arteriosus?: Evidence-based Medicine Viewpoint.
Topics: Ductus Arteriosus, Patent; Evidence-Based Medicine; Humans; Ibuprofen; Infant, Newborn; Infant, Prem | 2023 |
Is Expectant Management Noninferior to Early Ibuprofen for Patent Ductus Arteriosus?: Neonatologist's Viewpoint.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newborn; Infant, Premature; Neonatologists; Pe | 2023 |
Is Expectant Management Noninferior to Early Ibuprofen for Patent Ductus Arteriosus?: Pediatrician's Viewpoint.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newborn; Infant, Premature; Pediatricians; Per | 2023 |
Chiral pharmacokinetics of ibuprofen enantiomers in Chinese preterm neonates with patent ductus arteriosus using a validated UHPLC-MS/MS method.
Topics: Chromatography, High Pressure Liquid; Ductus Arteriosus, Patent; East Asian People; Humans; Ibuprofe | 2023 |
Neonatal ibuprofen exposure and bronchopulmonary dysplasia in extremely premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Bronchopulmonary Dysplasia; Confounding Facto | 2020 |
Patent ductus arteriosus closure: why same-dose oral ibuprofen is superior to intravenous.
Topics: Administration, Intravenous; Administration, Oral; Ductus Arteriosus, Patent; Humans; Ibuprofen; Inf | 2020 |
Neurodevelopmental Impairment at Two Years in Premature Infants with Prolonged Patency of Ductus Arteriosus after a Conservative Approach.
Topics: Child, Preschool; Conservative Treatment; Ductus Arteriosus, Patent; Female; Gestational Age; Humans | 2021 |
Ductal size indexed to weight and body surface area correlates with morbidities in preterm infants ≤32 weeks.
Topics: Body Surface Area; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Extremely Low Birth Weight; | 2021 |
[Clinical features and outcomes of neonatal necrotizing enterocolitis].
Topics: Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Humans; Ibuprofen; Infant, Newborn; Infant, P | 2019 |
The influence on renal function of ibuprofen treatment for patent ductus arteriosus in extremely low birthweight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Case-Control Studies; Ductus Arteriosus, Pate | 2020 |
Effects of maternal aspirin treatment on hemodynamically significant patent ductus arteriosus in preterm infants - pilot study.
Topics: Aspirin; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Newborn; Infant, Premature; P | 2022 |
Neonatal Intensive Care Unit-Level Patent Ductus Arteriosus Treatment Rates and Outcomes in Infants Born Extremely Preterm.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Canada; Cardiovascular Surgical Procedures; Cerebral | 2020 |
Plasma B-type natriuretic peptide cannot predict treatment response to ibuprofen in preterm infants with patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Birth Weight; Ductus Arteriosus, Patent; Female | 2020 |
Paracetamol for patent ductus arteriosus in preterm infants: a UK national survey.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Newborn; Infant, Premat | 2022 |
Paracetamol (Acetaminophen) for Patent Ductus Arteriosus: Where Do We Stand?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newbo | 2020 |
Simultaneous paracetamol may promote ibuprofen-induced closure of ductus arteriosus.
Topics: Acetaminophen; Administration, Intravenous; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non- | 2020 |
The Thromboelastographic Profile at Birth in Very Preterm Newborns with Patent Ductus Arteriosus.
Topics: Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infant; Infant, Extremely Premature; Infant, N | 2020 |
Effect of Nonintervention vs Oral Ibuprofen in Patent Ductus Arteriosus in Preterm Infants: A Randomized Clinical Trial.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Ductus Arteriosus, Pate | 2020 |
Paracetamol for Patent Ductus Arteriosus Closure: High Osmolality of Enteral Form and Spontaneous Intestinal Perforation.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Ductus Arteriosus, Patent; Humans; Ibuprofen; Intestinal Pe | 2020 |
Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus.
Topics: Birth Weight; Cholestasis; Ductus Arteriosus, Patent; Emulsions; Humans; Ibuprofen; Indomethacin; In | 2021 |
Drug exposure for PDA closure in France: a prospective, cohort-based, analysis.
Topics: Acetaminophen; Administration, Oral; Drug Resistance; Drug Utilization; Ductus Arteriosus, Patent; F | 2020 |
Aminoglycosides were associated with higher rates of surgical patent ductus arteriosus closure in preterm infants.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; | 2021 |
Comparison of the effect of continuous and standard intermittent bolus paracetamol infusion on patent ductus arteriosus.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Gestational Age; Humans; Ibuprofen; Infant; Infant, Newbor | 2021 |
Adverse events related to ibuprofen treatment for patent ductus arteriosus in premature neonates.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibuprofen; In | 2020 |
Association between changes in urine output and successful indomethacin treatment for patent ductus arteriosus in preterm neonates.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2021 |
PATENT DUCTUS ARTERIOSUS CLOSURE: EXPERIENCE FROM A TERTIARY REFERRAL CENTER.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibuprofen; Indomethacin; | 2020 |
Predictive factors for surgical treatment in preterm neonates with necrotizing enterocolitis: a multicenter case-control study.
Topics: Case-Control Studies; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Female; Humans; Ibuprof | 2021 |
Is ibuprofen superior to indomethacin for patent ductus arteriosus in Japanese preterm infants?
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant; Infant, Low Birth Weight; Infant | 2021 |
Ratio of arterial blood pressures at borders of window surrounding systolic peak indicates patent ductus arteriosus in preterm infants.
Topics: Arterial Pressure; Ductus Arteriosus, Patent; Gestational Age; Humans; Ibuprofen; Infant; Infant, Ne | 2021 |
Factors affecting the effectiveness of oral ibuprofen in the treatment of patent ductus arteriosus in preterm infants.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Low Birth Weight; Infant, Newborn; Infant, Pre | 2021 |
Cost-effectiveness of Oral Versus Intravenous Ibuprofen Therapy in Preterm Infants With Patent Ductus Arteriosus in the Neonatal Intensive Care Setting: A Cohort-based Study.
Topics: Administration, Oral; Cohort Studies; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Decision Tre | 2021 |
Nonintervention Is Not Noninferior to Oral Ibuprofen for Treatment of Patent Ductus Arteriosus-Reply.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Low Birth Weight; Infant, Newborn; Infant, Pre | 2021 |
Nonintervention Is Not Noninferior to Oral Ibuprofen for Treatment of Patent Ductus Arteriosus.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Low Birth Weight; Infant, Newborn; Infant, Pre | 2021 |
Association of hemoglobin and spontaneous closure of the ductus arteriosus during the transitional period in very low birth weight infants.
Topics: Case-Control Studies; Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Hemoglobins; Humans; Ibu | 2021 |
Comparison of standard versus high-dose ibuprofen for the treatment of hemodynamically significant patent ductus arteriosus in preterm infants.
Topics: Child, Preschool; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Low Birth Weight; In | 2021 |
The Effect of Dual (Combined) Treatment in Late Preterm Infants with Patent Ductus Arteriosus.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Newborn; Infant, Pr | 2022 |
Novel strategy to personalise use of ibuprofen for closure of patent ductus arteriosus in preterm neonates.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Drug Monitoring; Du | 2022 |
Part II. Acetaminophen and closure of ductus arteriosus in the newborns: Mechanisms of action, clinical studies, safety and efficacy.
Topics: Acetaminophen; Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newborn; Tre | 2021 |
Is intravenous paracetamol as effective as ibuprofen in closing haemodynamically significant patent ductus arteriosus after the first treatment course in preterm babies?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infan | 2021 |
Neonatal AKI in late preterm infants with patent ductus arteriosus.
Topics: Acute Kidney Injury; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Newborn; Infant, | 2021 |
Comparative Results of Treatment and Complications: Pedea in Open Ductus Arteriosus in Premature Infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cardiac Surgical Procedures; Clini | 2021 |
Oral paracetamol or oral ibuprofen to close the ductus arteriosus: both 'work', but do we know when to use them?
Topics: Acetaminophen; Administration, Oral; Analgesics, Non-Narcotic; Ductus Arteriosus; Ductus Arteriosus, | 2017 |
Using benchmarking to identify inter-centre differences in persistent ductus arteriosus treatment: can we improve outcome?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benchmarking; Cardiac Surgical Procedures; Ductus Arteriosu | 2017 |
[Digestive and Kidney Complications by indomethacin and ibuprofen in extreme preterm infants with patent ductus arteriosus].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Enterocolitis; Female; Humans; I | 2017 |
Trends in Patent Ductus Arteriosus Diagnosis and Management for Very Low Birth Weight Infants.
Topics: California; Cohort Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ib | 2017 |
Changes in the Diagnosis and Management of Patent Ductus Arteriosus from 2006 to 2015 in United States Neonatal Intensive Care Units.
Topics: Cyclooxygenase Inhibitors; Databases, Factual; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomet | 2017 |
Ibuprofen exposure in early neonatal life does not affect renal function in young adolescence.
Topics: Child; Child Development; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibuprofen; Inf | 2018 |
Risk Factors for the Development of Delayed TSH Elevation in Neonatal Intensive Care Unit Newborns.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Cefotaxime; Cesar | 2017 |
Oral Paracetamol for Patent Ductus Arteriosus Rescue Closure.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Drug Repositioning; Ductus Arteriosus, Patent; Echocardiogr | 2018 |
Neonatal gastric perforations in very low birth weight infants: a single center experience and review of the literature.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Asphyxia Neonatorum; Chorioamnionitis; Ductus Arteriosus, P | 2018 |
In a Resource-Limited Setting, Is Oral Ibuprofen Effective for Closure of a Patent Ductus Arteriosus in a Preterm Neonate?
Topics: Administration, Oral; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newborn; Infant, Prematu | 2018 |
Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus.
Topics: Acetaminophen; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Pat | 2018 |
Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion.
Topics: Chromatography, High Pressure Liquid; Ductus Arteriosus, Patent; Humans; Ibuprofen; Lipids; Parenter | 2018 |
Effect on cerebral oxygenation of paracetamol for patent ductus arteriosus in preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Blood Flow Velocity; Cerebrovascular Circulation; Ductus Ar | 2018 |
Is paracetamol as effective as indomethacin or ibuprofen in closing a hemodynamically significant patent ductus arteriosus in preterm infants?
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, | 2018 |
Patent ductus arteriosus in preterm infants born before 30 weeks' gestation: high rate of spontaneous closure after hospital discharge.
Topics: Administration, Intravenous; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Follow-Up | 2018 |
Simulation-based suggestions to improve ibuprofen dosing for patent ductus arteriosus in preterm newborns.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Computer | 2018 |
Reopening of the ductus arteriosus in preterm infants; Clinical aspects and subsequent consequences.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Ductus Arteriosus; Ductus | 2018 |
Effects of prophylactic oral ibuprofen on the closure rate of patent ductus arteriosus in premature infants.
Topics: Dinoprostone; Ductus Arteriosus, Patent; Echocardiography; Electrocardiography; Female; Gestational | 2018 |
Long-Term Neurodevelopment of Low-Birthweight, Preterm Infants with Patent Ductus Arteriosus.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Cyclooxygenase Inhibitors; Ductus Arteriosus, Pate | 2018 |
Exploration of potential biochemical markers for persistence of patent ductus arteriosus in preterm infants at 22-27 weeks' gestation.
Topics: Biomarkers; Chemokine CCL2; Ductus Arteriosus, Patent; Echocardiography; Growth Differentiation Fact | 2019 |
Impaired antimicrobial response and mucosal protection induced by ibuprofen in the immature human intestine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Culture Media, Serum-Free; Dinoprostone; Dose-Response Rela | 2018 |
What is the Most Efficacious Pharmacological Therapy for Patent Ductus Arteriosus Closure in Premature Infants?
Topics: Acetaminophen; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant; Infant, Newborn; | 2018 |
Comparison of efficacy of paracetamol and ibuprofen in preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infan | 2020 |
Does Postmenstrual Age Affect Medical Patent Ductus Arteriosus Treatment Success in Preterm Infants?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; | 2019 |
Comparison of efficacy and safety of oral ibuprofen versus oral indomethacin.
Topics: Birth Weight; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, V | 2019 |
Early haemodynamically significant patent ductus arteriosus does not predict future persistence in extremely preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echocardiography; Female; Hemody | 2019 |
Efficacy and Safety of Oral Paracetamol vs. Oral Ibuprofen in the Treatment of Symptomatic Patent Ductus Arteriosus in Premature Infants.
Topics: Acetaminophen; Administration, Oral; Analgesics, Non-Narcotic; Ductus Arteriosus, Patent; Gestationa | 2019 |
Useful Platelet Indices for the Diagnosis and Follow-Up of Patent Ductus Arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Cell Count; Case-Control Studies; Drug Resistance; Du | 2019 |
Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen | 2019 |
Patent ductus arteriosus in preterm infants born at 23-24 weeks' gestation: Should we pay more attention?
Topics: Cardiac Surgical Procedures; Disease Management; Ductus Arteriosus, Patent; Echocardiography; Female | 2019 |
Vascular endothelial growth factor polymorphism rs2010963 status does not affect patent ductus arteriosus incidence or cyclooxygenase inhibitor treatment success in preterm infants.
Topics: Case-Control Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofe | 2019 |
Reply to letter to the editor: Comparison of efficacy and safety of oral ibuprofen versus oral indomethacin.
Topics: Birth Weight; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, V | 2019 |
Cerebral perfusion and assessing hemodynamic significance for patent ductus arteriosus using near infrared red spectroscopy in very low birth weight infants.
Topics: Cerebrovascular Circulation; Ductus Arteriosus, Patent; Hemodynamics; Humans; Ibuprofen; Infant; Inf | 2021 |
Oral ibuprofen is superior to oral paracetamol for patent ductus arteriosus in very low and extremely low birth weight infants.
Topics: Acetaminophen; Administration, Oral; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Du | 2019 |
Prevalence and management of patent ductus arteriosus in a pediatric medicaid cohort.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiac Surgical Procedures; Ductus Arteriosus, Patent; Ech | 2013 |
Renal and mesenteric tissue oxygenation in preterm infants treated with oral ibuprofen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Gestational Age; Hemodynamics; H | 2014 |
"Shunt index" can be used to predict clinically significant patent ductus arteriosus in premature neonates in early post-natal life.
Topics: Arteries; Blood Gas Analysis; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography | 2014 |
Early paracetamol treatment associated with lowered risk of persistent ductus arteriosus in very preterm infants.
Topics: Acetaminophen; Birth Weight; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibuprofen; | 2014 |
Early paracetamol treatment associated with lowered risk of persistent ductus arteriosus in very preterm infants.
Topics: Acetaminophen; Birth Weight; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibuprofen; | 2014 |
Early paracetamol treatment associated with lowered risk of persistent ductus arteriosus in very preterm infants.
Topics: Acetaminophen; Birth Weight; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibuprofen; | 2014 |
Early paracetamol treatment associated with lowered risk of persistent ductus arteriosus in very preterm infants.
Topics: Acetaminophen; Birth Weight; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibuprofen; | 2014 |
Outcomes of primary ligation of patent ductus arteriosus compared with secondary ligation after pharmacologic failure in very-low-birth-weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiac Surgical Procedures; Ductus Arteriosus, Patent; Fem | 2014 |
Lethal pulmonary hypertension associated with ibuprofen treatment in a very low birth weight infant.
Topics: Ductus Arteriosus, Patent; Fatal Outcome; Humans; Hypertension, Pulmonary; Ibuprofen; Infant, Extrem | 2014 |
Ibuprofen versus indomethacin treatment of patent ductus arteriosus: comparative effectiveness and complications.
Topics: Bronchopulmonary Dysplasia; Creatinine; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indome | 2014 |
Acetaminophen: a possible alternative to ibuprofen in patent ductus arteriosus closure.
Topics: Acetaminophen; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen | 2014 |
Hospital variation in medical and surgical treatment of patent ductus arteriosus.
Topics: Birth Weight; California; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Gestational | 2015 |
Variation and comparative effectiveness of patent ductus arteriosus pharmacotherapy in extremely low birth weight infants.
Topics: Cohort Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Ind | 2014 |
Indomethacin vs ibuprofen: comparison of efficacy in the setting of conservative therapeutic approach.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Creatinine; Ductus Arteriosus, Patent; Female | 2015 |
Timing of pharmacological treatment for patent ductus arteriosus and risk of secondary surgery, death or bronchopulmonary dysplasia: a population-based cohort study of extremely preterm infants.
Topics: Bronchopulmonary Dysplasia; Cohort Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Fe | 2015 |
Impact of patent ductus arteriosus and subsequent therapy with ibuprofen on the release of S-100B and oxidative stress index in preterm infants.
Topics: Antioxidants; Case-Control Studies; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infant, Ne | 2014 |
Antioxidants and Biomarkers of Oxidative Stress in Preterm Infants with Symptomatic Patent Ductus Arteriosus.
Topics: Antioxidants; Biomarkers; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibup | 2015 |
The importance of echocardiography and an individual approach to patent ductus arteriosus treatment in extremely preterm infants.
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ib | 2015 |
Adequate timely treatment of patent ductus arteriosus in extremely low birth weight infants: an ongoing challenge.
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ib | 2015 |
Efficacy of a first course of Ibuprofen for patent ductus arteriosus closure in extremely preterm newborns according to their gestational age-specific Z-score for birth weight.
Topics: Age Factors; Birth Weight; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Gestational | 2015 |
Limited effects of intravenous paracetamol on patent ductus arteriosus in very low birth weight infants with contraindications for ibuprofen or after ibuprofen failure.
Topics: Acetaminophen; Administration, Intravenous; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non- | 2015 |
Future Benefits of Sequential Echocardiography: Unmasking the Indications for Treatment of Patent Ductus Arteriosus in Extremely Preterm Infants.
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ib | 2015 |
[Clinical characteristics and cardiac hemodynamic changes of patent ductus ateriosus in preterm infants].
Topics: Birth Weight; Bronchopulmonary Dysplasia; Cardiac Output; Cyclooxygenase Inhibitors; Ductus Arterios | 2015 |
Comparative effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus.
Topics: Cardiovascular Agents; Databases, Factual; Ductus Arteriosus, Patent; Female; Gestational Age; Human | 2015 |
Current Status of Therapeutic Strategies for Patent Ductus Arteriosus in Very-Low-Birth-Weight Infants in Korea.
Topics: Cohort Studies; Databases, Factual; Ductus Arteriosus, Patent; Echocardiography; Gestational Age; Hu | 2015 |
Neurodevelopmental Outcome at 2 Years of Age according to Patent Ductus Arteriosus Management in Very Preterm Infants.
Topics: Child, Preschool; Cohort Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibup | 2016 |
Treatment of Patent Ductus Arteriosus with Cyclo-oxygenase Inhibitors beyond 2 Weeks of Age in Very Low Birth Weight Infants.
Topics: Connecticut; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indome | 2016 |
Does platelet mass influence the effectiveness of ibuprofen treatment for patent ductus arteriosus in preterm infants?
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infant, Newborn; In | 2016 |
Nonsteroidal anti-inflammatory administration and patent ductus arteriosus ligation, a survey of practice preferences at US children's hospitals.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Consensus; Cyclooxygenase Inhibitors; Ductus Arteriosus, Pa | 2016 |
Oral Paracetamol for Closure of Patent Ductus Arteriosus in Selected Preterm Neonates.
Topics: Acetaminophen; Administration, Oral; Contraindications; Ductus Arteriosus, Patent; Humans; Ibuprofen | 2016 |
Intravenous paracetamol for PDA closure in the preterm: a single-center experience.
Topics: Acetaminophen; Administration, Intravenous; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Ec | 2016 |
Editorial: Patent Ductus Arteriosus in Extremely Premature Neonates.
Topics: Anterior Cerebral Artery; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography, Do | 2016 |
Repeated Courses of Oral Ibuprofen in Premature Infants with Patent Ductus Arteriosus: Efficacy and Safety.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Gestational Age; | 2017 |
The serial changes of perfusion index in preterm infants with patent ductus arteriosus: is perfusion index clinically significant?
Topics: Administration, Intravenous; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; Ductu | 2016 |
Effectiveness and safety of treatments used for the management of patent ductus arteriosus (PDA) in preterm infants: a protocol for a systematic review and network meta-analysis.
Topics: Acetaminophen; Administration, Oral; Bayes Theorem; Cyclooxygenase Inhibitors; Ductus Arteriosus, Pa | 2016 |
The Role of Paracetamol for Closing Patent Ductus Arteriosus. A Challenging Alternative for Ductal Closure?
Topics: Acetaminophen; Administration, Intravenous; Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorr | 2016 |
Trends and variation in management and outcomes of very low-birth-weight infants with patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Databases, Factual; Ductus Arteriosus, Patent; Female; Hospitals, Pediatr | 2016 |
Pulmonary Arterial Hypertension after Ibuprofen Treatment for Patent Ductus Arteriosus in Very Low Birth Weight Infants.
Topics: Cohort Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Hypertension, | 2016 |
Comparison of the Mortality and In-Hospital Outcomes of Preterm Infants Treated with Ibuprofen for Patent Ductus Arteriosus with or without Clinical Symptoms Attributable to the Patent Ductus Arteriosus at the Time of Ibuprofen Treatment.
Topics: Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Echocardiography; Entero | 2017 |
Pulmonary arterial hypertension after ibuprofen treatment in the first week of life?
Topics: Ductus Arteriosus, Patent; Humans; Hypertension, Pulmonary; Ibuprofen; Infant, Premature | 2017 |
Management of Patent Ductus Arteriosus: Are We Looking at the Right Outcomes?
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, Premature; Pers | 2017 |
A conservative treatment of patent ductus arteriosus in very low birth weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infan | 2017 |
Efficacy of Repeated Courses of Ibuprofen in the Closure of Patent Ductus Arteriosus in Premature Infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Human | 2017 |
Oral ibuprofen for patent ductus arteriosus closure in preterm infants: does high osmolality matter?
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ib | 2008 |
The fate of ductus arteriosus in infants at 23-27 weeks of gestation: from spontaneous closure to ibuprofen resistance.
Topics: Blood Coagulation; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Resistance; Duc | 2008 |
Total serum bilirubin levels during cyclooxygenase inhibitor treatment for patent ductus arteriosus in preterm infants.
Topics: Bilirubin; Child, Preschool; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Hemodynam | 2009 |
Changes in urinary PGE2 after ibuprofen treatment in preterm infants with patent ductus arteriosus.
Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Creatinine; Dinoprostone; Ductus Arter | 2009 |
Factors affecting postnatal changes in serum creatinine in preterm infants with gestational age <32 weeks.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Creatinine; Ductus Arteriosus, Patent; Female; Gestational | 2009 |
[First SIBEN clinical consensus: diagnostic and therapeutic approach to patent ductus arteriosus in premature newborns].
Topics: Age Factors; Brain Diseases; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Diuretics; Ductus Art | 2008 |
Delayed neonatal closure of the ductus arteriosus following early in utero exposure to indomethacin in the rat.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibito | 2009 |
Oral versus intravenous ibuprofen: which is better in closure of patent ductus arteriosus?
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ib | 2009 |
Is there an optimal timing for surgical ligation of patent ductus arteriosus in preterm infants?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apgar Score; Birth Weight; Ductus Arteriosus, Patent; Femal | 2009 |
Vascular abnormalities in aggressive posterior retinopathy of prematurity detected by fluorescein angiography.
Topics: Capillary Permeability; Ductus Arteriosus, Patent; Female; Fluorescein Angiography; Gestational Age; | 2009 |
Does Ibuprofen increase neonatal hyperbilirubinemia?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bilirubin; Cohort Studies; Ductus Arteriosus, Patent; Femal | 2009 |
A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Creatinine; Dose-Response Relationship, Dru | 2009 |
Hormonal influences of early postnatal indomethacin and ibuprofen in neonatal rats.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Carrier Proteins; Corticosterone | 2010 |
[Patent ductus arteriosus in premature infants].
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Hemodynamics; Huma | 2009 |
The impact of an early Ibuprofen treatment protocol on the incidence of surgical ligation of the ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infant, Newborn; In | 2010 |
N-terminal-pro-B-type natriuretic peptide in premature patent ductus arteriosus: a physiologic biomarker, but is it a clinical tool?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Drug Monitoring; Ductus Arteriosus, Patent; Hum | 2010 |
Treatment of patent ductus arteriosus: indomethacin or ibuprofen?
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indomethacin; Infan | 2010 |
Safety and effectiveness of indomethacin versus ibuprofen for treatment of patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Male; Retrospec | 2010 |
Neurodevelopmental outcome after COX inhibitor treatment for patent ductus arteriosus.
Topics: Central Nervous System; Child Development; Child, Preschool; Cyclooxygenase Inhibitors; Ductus Arter | 2010 |
Effect of ibuprofen on bilirubin-albumin binding in vitro at concentrations observed during treatment of patent ductus arteriosus.
Topics: Albumins; Analgesics, Non-Narcotic; Bilirubin; Binding Sites; Dose-Response Relationship, Drug; Duct | 2010 |
Ibuprofen treatment for closure of patent ductus arteriosus is not associated with increased risk of neuropathology.
Topics: Animals; Animals, Newborn; Astrocytes; Brain; Cyclooxygenase Inhibitors; Disease Models, Animal; Duc | 2010 |
Echocardiography predicts closure of patent ductus arteriosus in response to ibuprofen in infants less than 28 week gestational age.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echocardiography; Female; Gestat | 2010 |
Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants?
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Ductus Arteriosus, | 2010 |
Isoprostane levels in urine of preterm newborns treated with ibuprofen for patent ductus arteriosus closure.
Topics: Antioxidants; Ductus Arteriosus, Patent; Female; Free Radicals; Humans; Ibuprofen; Infant, Newborn; | 2011 |
Effect of ibuprofen on bilirubin-albumin binding affinity in premature infants.
Topics: Albumins; Bilirubin; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Hyperbili | 2011 |
Aminoterminal B-type natriuretic peptide (NT-proBNP) in the therapy of patent ductus arteriosus.
Topics: Biomarkers; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibuprofen; Infant, Extremely | 2010 |
Patent ductus arteriosus ligation alters pulmonary gene expression in preterm baboons.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Femal | 2011 |
Urinary aquaporin-2 excretion during ibuprofen or indomethacin treatment in preterm infants with patent ductus arteriosus.
Topics: Aquaporin 2; Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibup | 2011 |
Gastrointestinal complications associated with ibuprofen therapy for patent ductus arteriosus.
Topics: Cohort Studies; Confidence Intervals; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; D | 2011 |
Patent ductus arteriosus in the preterm infant: a survey of clinical practices in French neonatal intensive care units.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Contraindications; Data Collection; Dose-Response Relations | 2011 |
Treatment of patent ductus arteriosus with bidirectional flow in neonates.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Ductus Arteriosus, Patent; Echocardiography | 2011 |
Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) neonates.
Topics: Adult; Aging; Anti-Inflammatory Agents, Non-Steroidal; Apgar Score; Birth Weight; Cohort Studies; Cr | 2011 |
Comparison of renal effects of ibuprofen versus indomethacin during treatment of patent ductus arteriosus in contiguous historical cohorts.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Creatinine; Ductus Arteriosus, Patent; Fema | 2011 |
The effects of ibuprofen on sepsis parameters in preterm neonates.
Topics: Anti-Inflammatory Agents, Non-Steroidal; C-Reactive Protein; Case-Control Studies; Ductus Arteriosus | 2012 |
Update on management of patent ductus arteriosus in the preterm infant.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; | 2011 |
Ibuprofen lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newborn; Infant, Pr | 2012 |
Oral ibuprofen for the treatment of patent ductus arteriosus: further clarification.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Premature, Diseases | 2012 |
Pharmacokinetics of oral ibuprofen for patent ductus arteriosus closure in preterm infants.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infan | 2012 |
Failure of a repeat course of cyclooxygenase inhibitor to close a PDA is a risk factor for developing chronic lung disease in ELBW infants.
Topics: Chronic Disease; Cyclooxygenase Inhibitors; Drug Administration Schedule; Ductus Arteriosus, Patent; | 2012 |
Effects of ibuprofen treatment on the developing preterm baboon kidney.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Body Weight; Dri | 2012 |
Oral ibuprofen for patent ductus arteriosus: effective and safe or just cheap? Commentary on R. Neumann et al.: Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a sys
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin | 2012 |
Does treatment of patent ductus arteriosus with cyclooxygenase inhibitors affect neonatal regional tissue oxygenation?
Topics: Analysis of Variance; Blood Gas Analysis; Cerebrovascular Circulation; Chi-Square Distribution; Chro | 2012 |
Severe pulmonary hypertension with therapeutic L-lysine ibuprofen in 2 preterm neonates.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diseases in Twins; Ductus Arteriosus, Patent; Echocardiogra | 2012 |
An unreported complication of intravenously administered ibuprofen: gastrointestinal bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Gastrointestinal Hemorrhage; Hum | 2012 |
Early treatment of the patent ductus arteriosus: do we know what we are doing?.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echocardiography, Doppler, Color | 2012 |
Patent ductus arteriosus in premature neonates.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2012 |
Ibubrofen in the treatment of patent ductus arteriosus in preterm infants: what we know, what we still do not know.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Evidence-Based Medicine | 2012 |
The patent ductus arteriosus controversy.
Topics: Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infant, Premature; Male; Respiration | 2012 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
Oral ibuprofen for treatment of patent ductus arteriosus: more than a cheap alternative?
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin | 2012 |
Pulmonary hypertension in an infant treated with ibuprofen.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Hypertension, Pulmonary; Ibuprofen; In | 2013 |
Repeated courses of ibuprofen are effective in closure of a patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Drug Administration Schedule; Ductus Arteriosus, Patent; Female; Humans; | 2012 |
Thrombocytopenia in the first 24 hours after birth and incidence of patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography, Doppler; Female; Humans; Ibu | 2012 |
Relationship between platelet count and volume and spontaneous and pharmacological closure of ductus arteriosus in preterm infants.
Topics: Blood Platelets; Cell Size; Cohort Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Fe | 2013 |
High-dose Ibuprofen therapy for patent ductus arteriosus in extremely preterm neonates: do we have a final answer?
Topics: Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infant, Extremely Low Birth Weight; Male | 2012 |
Impact of patient selection on outcomes of PDA in very low birth weight infants.
Topics: Administration, Oral; Birth Weight; Ductus Arteriosus, Patent; Echocardiography; Female; Gestational | 2013 |
Comparative evaluation for the use of oral ibuprofen and intravenous indomethacin in Korean infants with patent ductus.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Ductus Arteriosus, Paten | 2012 |
Elevated urinary NT-proBNP after pharmacological closure of patent ductus arteriosus in very low birth weight infants.
Topics: Biomarkers; Creatine; Ductus Arteriosus, Patent; Echocardiography, Doppler; Enzyme-Linked Immunosorb | 2013 |
Oral ibuprofen versus intravenous indomethacin for closure of patent ductus arteriosus in very low birth weight infants.
Topics: Administration, Intravenous; Administration, Oral; Ductus Arteriosus, Patent; Enterocolitis, Necroti | 2012 |
Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Fema | 2013 |
Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants.
Topics: Ductus Arteriosus, Patent; Humans; Hypertension, Pulmonary; Ibuprofen; Infant, Newborn; Infant, Prem | 2002 |
Ibuprofen for closure of patent ductus arteriosus: is it really safe in hyperbilirubinaemic infants?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Hyperbilirubinemia; Ibup | 2003 |
Blood withdrawal and infusion via umbilical catheters: effect on cerebral perfusion and influence of ibuprofen.
Topics: Arteries; Blood Pressure; Blood Specimen Collection; Blood Transfusion; Blood Volume; Catheterizatio | 2003 |
Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: a pilot study.
Topics: Administration, Oral; Cerebral Hemorrhage; Drug Evaluation; Ductus Arteriosus, Patent; Gestational A | 2003 |
Spontaneous intestinal perforation after oral ibuprofen treatment of patent ductus arteriosus in two very-low-birthweight infants.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Hu | 2004 |
Efficacy and renal tolerability of ibuprofen vs. indomethacin in preterm infants with patent ductus arteriosus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen | 2005 |
Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arginine Vasopressin; Cyclooxygenase 2 Inhibitors; Ductus A | 2005 |
Consequences of delayed surgical closure of patent ductus arteriosus in very premature infants.
Topics: Combined Modality Therapy; Ductus Arteriosus, Patent; Enteral Nutrition; Female; Gestational Age; Hu | 2006 |
Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Fatal Outcome; Humans; Hypertens | 2006 |
Conservative treatment for patent ductus arteriosus in the preterm.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Femal | 2007 |
Acute renal impairment after oral ibuprofen for medical closure of patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infan | 2007 |
Oral ibuprofen in early curative closure of patent ductus arteriosus in very premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echocardiography, Doppler, Color | 2007 |
Early postnatal ibuprofen and indomethacin effects in suckling and weanling rat kidneys.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin II; Animals; Animals, Newborn; Animals, Suckling; Cyclooxy | 2008 |
Ductus arteriosus ligation and alveolar growth in preterm baboons with a patent ductus arteriosus.
Topics: Animals; Blood Pressure; Cardiac Surgical Procedures; Disease Models, Animal; Ductus Arteriosus, Pat | 2008 |
An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Ductus Arteriosus, Patent; Humans; Ibupro | 2008 |
Ibuprofen-induced patent ductus arteriosus closure: physiologic, histologic, and biochemical effects on the premature lung.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Bronchoalveolar Lavage Fluid; Du | 2008 |
Use of ibuprofen in unusual circumstances.
Topics: Arthritis, Rheumatoid; Aspirin; Bartter Syndrome; Cyclooxygenase Inhibitors; Digoxin; Drug Hypersens | 1984 |
Comparative effects of indomethacin, prostaglandin E1, and ibuprofen on bowel ischemia.
Topics: Alprostadil; Animals; Ductus Arteriosus, Patent; Enterocolitis, Pseudomembranous; Ibuprofen; Indomet | 1983 |
Ibuprofen treatment of patent ductus arteriosus.
Topics: Brain; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Gestational Age; Humans; Ibuprofen; I | 1995 |
Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant.
Topics: Age Factors; Binding Sites; Cerebral Hemorrhage; Chromatography, High Pressure Liquid; Cyclooxygenas | 1997 |
Is ibuprofen a useful treatment for patent ductus arteriosus?
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newborn | 1998 |
Cerebral vasoreactivity to arterial carbon dioxide tension in preterm infants: the effect of ibuprofen.
Topics: Brain; Carbon Dioxide; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Hemoglobins; Humans; | 1999 |
Back to the drawing board.
Topics: Brain; Ductus Arteriosus, Patent; Echocardiography; Humans; Ibuprofen; Indomethacin; Infant, Newborn | 2000 |
Ibuprofen as effective as indomethacin for patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, Premature; Olig | 2000 |
Ibuprofen and patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2000 |
Don't discard your indomethacin yet.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Brain; Cerebral Hemorrhage; Clinical Trials a | 2000 |
[Patent ductus arteriosus is still a clinical problem in extremely premature infants. Time to make the indications for diagnosis and treatment more stringent].
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newborn; Infant, Pr | 2000 |
Ibuprofen versus indomethacin for closure of patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2001 |
Ibuprofen-lysine for closure of patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Ductus Arteriosus, Patent; Humans; Ibupr | 2001 |
Oral ibuprofen for closure of hemodynamically significant PDA in premature neonates.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ib | 2002 |
Clinical trials: when to start and when to stop.
Topics: Analgesics, Non-Narcotic; Ductus Arteriosus, Patent; Humans; Hypertension, Pulmonary; Ibuprofen; Inf | 2002 |